



THE UNIVERSITY
of ADELAIDE

DYNAMIC EQUINE LARYNGEAL PROSTHESIS

Benjamin J Ahern

BVSc (Hons I) MANZCVS DACVS DACVSMR

A thesis submitted for the degree of Doctor of Philosophy at

The University of Adelaide 2017

School of Animal and Veterinary Sciences

Table of Contents

ABSTRACT	4
DECLARATION BY AUTHOR	6
ACKNOWLEDGEMENTS	7
PUBLICATIONS INCLUDED IN THE THESIS	8
<i>Peer-reviewed papers</i>	8
KEYWORDS	9
AUSTRALIAN AND NEW ZEALAND STANDARD RESEARCH CLASSIFICATIONS (ANZSRC)	9
FIELDS OF RESEARCH (FOR) CLASSIFICATION	9
PART I: GENERAL INTRODUCTION	10
CHAPTER 1: INTRODUCTION, LITERATURE REVIEW AND PROJECT AIMS	11
1.1 <i>Introduction</i>	11
1.2 <i>Equine Laryngeal Anatomy</i>	13
1.3 <i>Respiratory physiology related to laryngeal dysfunction</i>	15
1.4 <i>Aetiology and pathophysiology of RLN</i>	16
1.5 <i>Diagnosis of RLN</i>	17
1.6 <i>Treatment options for RLN</i>	20
1.7 <i>Current Laryngoplasty Techniques, Success Rates and Complications</i>	21
1.8 <i>Biomechanics of Laryngoplasty</i>	25
1.9 <i>Conclusions</i>	30
1.10 <i>Project Aims and Hypotheses</i>	31
PART II: PROTOTYPE CONCEPTUALISATION, DEVELOPMENT AND OPTIMISATION	33
CHAPTER 2: PROTOTYPE DEVELOPMENT	34
2.1 <i>Introduction</i>	34
2.2 <i>Conceptualisation</i>	34
2.3 <i>Prototype versions</i>	37
2.4 <i>Prototype evaluations</i>	40
2.5 <i>Cadaveric testing of deliverability / functionality</i>	41
2.6 <i>Discussion</i>	43
CHAPTER 3: <i>IN VITRO</i> COMPARISON OF 3 TECHNIQUES OF PROSTHESIS ATTACHMENT TO THE MUSCULAR PROCESS OF THE EQUINE ARYTENOID CARTILAGE	44
<i>Statement of authorship</i>	44
3.1 <i>Abstract</i>	46
3.2 <i>Introduction</i>	47
3.3 <i>Materials and methods</i>	49
3.4 <i>Results</i>	50
3.5 <i>Discussion</i>	51
PART III: <i>IN VITRO</i> PROTOTYPE EVALUATION STUDIES	55
CHAPTER 4: MECHANICAL TESTING OF A PROTOTYPE DYNAMIC LARYNGOPLASTY SYSTEM (DLPS)	56
<i>Statement of authorship</i>	56
4.1 <i>Abstract</i>	58
4.2 <i>Introduction</i>	59
4.3 <i>Materials and Methods</i>	61
4.4 <i>Results</i>	63
4.5 <i>Discussion</i>	65

CHAPTER 5: <i>IN VITRO</i> EVALUATION OF THE EFFECT OF A PROTOTYPE DYNAMIC LARYNGOPLASTY SYSTEM (DLPS) ON ARYTENOID ABDUCTION	69
<i>Statement of authorship</i>	69
5.1 <i>Abstract</i>	71
5.2 <i>Introduction</i>	73
5.3 <i>Materials and Methods</i>	74
5.4 <i>Results</i>	78
5.5 <i>Discussion</i>	80
CHAPTER 6: EVALUATION OF A PROTOTYPE DYNAMIC LARYNGOPLASTY SYSTEM (DLPS) <i>IN VITRO</i> USING AN EQUINE VACUUM AIRFLOW SYSTEM.....	84
<i>Statement of authorship</i>	84
6.1 <i>Abstract</i>	87
6.2 <i>Introduction</i>	89
6.3 <i>Materials and Methods</i>	91
6.4 <i>Results</i>	96
6.5 <i>Discussion</i>	101
PART IV: <i>IN VIVO</i> PROOF OF CONCEPT STUDY	106
CHAPTER 7: <i>IN VIVO</i> EVALUATION OF A PROTOTYPE DYNAMIC LARYNGOPLASTY SYSTEM (DLPS) IN HORSES	107
<i>Statement of authorship</i>	107
7.1 <i>Abstract</i>	109
7.2 <i>Introduction</i>	111
7.3 <i>Materials and Methods</i>	111
7.4 <i>Results</i>	115
7.5 <i>Discussion</i>	118
PART V: CONCLUSION.....	122
CHAPTER 8: GENERAL DISCUSSION.....	123
REFERENCES.....	126

ABSTRACT

The respiratory system of horses is the major limiting factor for athletic performance. As such, any respiratory impairment can have a considerable effect on athletic performance. A common site for this impairment to occur is the upper respiratory tract with laryngeal collapse being the most common form in horses. The recurrent laryngeal nerves in the horse are the longest nerves in the body and prone to degenerative axonopathy. This is termed recurrent laryngeal neuropathy (RLN) and results in neurogenic atrophy of the cricoarytenoideus dorsalis (CAD) muscle. Loss of function of the CAD leads to dynamic laryngeal collapse when exposed to the negative airway pressures produced during exercise. As a result, RLN is a common cause of reduced athletic performance in horses. Currently the most commonly performed treatment for RLN in horses is a static prosthetic laryngoplasty. This procedure has a relatively poor success rate in performance horses (ranging from 50-70%) and high complication rate of between 26-43%.¹⁻⁴ Two of the major complications are dysphagia and loss of abduction. In general, many of the complications can be attributed to either under or over abduction of the arytenoid and static laryngoplastic fixation.

The objective of the research reported here was to develop a laryngoplasty system that allowed for alteration of the degree of arytenoid abduction post-operatively. This thesis outlines the successful development of such a device.

Initially, the existing standard laryngoplasty procedure was examined mechanically and a variety of prototypes were developed and evaluated. Subsequently, we selected the final dynamic laryngoplasty system (DLPS) for further evaluation. After optimising the position of attachment to the arytenoid using an anchor, the prototype device was mechanically tested under static loading, cyclic and ramp (single linear loading) to failure conditions. This study found the device was able to cause effective shortening of a suture loop with

minimal cyclical loss and was able to resist ramp testing sufficiently to justify further evaluation. Additional *in vitro* testing was performed using cadaveric larynges and demonstrated that the DLPS was able to cause effective increases in arytenoid abduction within the confines of equine laryngeal anatomy. The final *in vitro* study tested the ability of the DLPS to achieve and maintain arytenoid abduction during testing using a static airflow model with a flow rate of 55L/sec which was consistent with previously published research. After completion of the *in vitro* studies an *in vivo* proof of concept study was performed. This demonstrated that the device could be effectively delivered via a standing procedure under sedation and allowed for selective alteration in arytenoid abduction at 7 days post-operatively.

DECLARATION BY AUTHOR

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I acknowledge that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

I acknowledge the support I have received for my research through the provision of an Australian Government Research Training Program Scholarship.

Benjamin Ahern

10 June 2017

ACKNOWLEDGEMENTS

I would like to thank my supervisors Samantha Franklin and Andrew Van Eps for their much-valued support, guidance and patience during this process. Eric Parente is sincerely thanked for kindling my enthusiasm in this area of equine surgery during many a laryngoplasty procedure whilst I was a house officer at New Bolton Centre. My parents have been a continued source of encouragement for all my life and are truly amazing role models. A special note to my father to acknowledge him teaching me what a PhD meant. Finally, my wife Karen who is an unending source of inspiration to me on a daily basis I profoundly thank for innumerable reasons.

PUBLICATIONS INCLUDED IN THE THESIS

Peer-reviewed papers

B.J. Ahern, A.W. Van Eps, R.C. Boston, S.H. Franklin (2017). *In vitro* comparison of 3 techniques of prosthesis attachment to the muscular process of the equine arytenoid cartilage. *Veterinary Surgery* April 29th 2017 [Epub ahead of print]

B.J. Ahern, A.W. Van Eps, S.H. Franklin. Mechanical testing of a prototype dynamic laryngoplasty system (DLPS). *Submitted to Veterinary Surgery*

B.J. Ahern, Y Lim, A.W. Van Eps, S.H. Franklin. *In vitro* evaluation of the efficacy of a prototype dynamic laryngoplasty system (DLPS) to affect arytenoid abduction. *Submitted to Veterinary Surgery*

B.J. Ahern, E. Lukas, K. Lam, E. Wilke, F.R. Bertin, A.W. Van Eps, S.H. Franklin. Evaluation of a prototype dynamic laryngoplasty system (DLPS) *in vitro* using an static airflow system. *Submitted to Veterinary Surgery*

B.J. Ahern, A.W. Van Eps, S.H. Franklin. *In vivo* evaluation of a prototype dynamic laryngoplasty system (DLPS) in horses. *Submitted to Veterinary Surgery*

KEYWORDS

Equine, larynx, laryngoplasty, dynamic laryngoplasty system, DLPS, tie-back, recurrent laryngeal neuropathy (RLN)

AUSTRALIAN AND NEW ZEALAND STANDARD RESEARCH CLASSIFICATIONS (ANZSRC)

ANZSRC code: 070711, Veterinary Surgery 80%

ANZSRC code: 070702, Veterinary Anatomy and Physiology 20%

FIELDS OF RESEARCH (FoR) CLASSIFICATION

FoR code: 0707, Veterinary Science, 100%

PART I: GENERAL INTRODUCTION

Chapter 1: Introduction, literature review and project aims

1

2

3 1.1 Introduction

4 The major limiting factor in a horses' exercising capacity is the respiratory system.⁵ Within
5 this system the upper airway is a common site of obstruction to airflow that can result in
6 poor performance. The importance of the respiratory system in horses is illustrated by the
7 massive increase in airflow associated with exercise. At rest horses have a tidal volume of
8 approximately 5 L and breathing rate of 15 breaths per minute leading to a minute
9 ventilation of 75 L per minute. With exercise this increases by between 20-60 times to
10 1200-2580 L per minute.⁶⁻¹⁰ These massive airflow rates lead to large negative airway
11 pressures affecting the upper airway.^{6,11} Peak negative airway pressure during inhalation
12 has been reported to range from 3922 to 4903 Pa whilst galloping at 14m/sec on a
13 treadmill with a peak inspiratory flow rate of 2580L/min.^{9,12} Humans in comparison have a
14 negative pressure of only 441 Pa during a forceful sniff with a flow rate of 1.1L/sec.^{12,13}
15 Horses are obligate nasal breathers. This means they are unable to breathe through the oral
16 cavity and all air has to pass through the nares. As a result, horses must accommodate the
17 massive increases in airflow of exercise solely through the nasal cavity. During inspiration
18 90% of the resistance to airflow is attributed to the upper airway and this is evenly
19 distributed between the nares and the larynx.^{6,12} The nares are rarely a cause of clinically
20 relevant increases in airway resistance in horses. However, in contrast, the larynx is an
21 important site of increased airflow resistance even in a normal functioning state. When the
22 larynx is dysfunctional it can cause a massive negative effect on airflow and performance
23 as a result.

24 The larynx is short tube that connects the pharynx to the trachea.¹⁴ It is an anatomical

25 structure that is uniquely required to serve two major functions: facilitating airflow during
26 breathing; and preventing water and food from entering the trachea during deglutition. To
27 achieve its required functions the larynx needs to be able to close fully during swallowing
28 and then open maximally during exercise. Abduction of the arytenoid cartilages results in
29 enlargement of the *rima glottidis* and is controlled in the horse by a single pair of muscles
30 called the *cricoarytenoideus dorsalis* (CAD). These muscles, one on each side of the
31 larynx, are solely responsible for opening each hemi-larynx to a point that they minimally
32 obstruct airflow. These muscles are innervated by the left and recurrent laryngeal nerves
33 which are branches of the vagus. The left recurrent laryngeal nerve is the longest nerve in
34 the horse's body measuring up to 250 cm in length, twice as long as other motor nerves in
35 the horse and approximately 31 cm longer than the right side.¹⁵ The greater length on the
36 left is due to the nerve coursing around the aortic arch, compared with the right which does
37 not. As a result of this unique anatomy the left recurrent laryngeal nerve has historically
38 been thought to be most susceptible to degeneration. However, the role of nerve length in
39 the pathogenesis of this degeneration is uncertain at this stage.¹⁶ Degeneration of the
40 recurrent laryngeal nerve is commonly termed recurrent laryngeal neuropathy (RLN). This
41 nerve dysfunction then leads to CAD muscle atrophy and hence an inability to sufficiently
42 abduct the affected left arytenoid cartilage.¹⁷⁻²⁰ When complete, this has been termed
43 laryngeal hemiplegia (LH). This reduction in the ability to open the larynx causes
44 increased resistance to airflow and results in reduced oxygen delivery leading to reduced
45 athletic performance.^{21,22}


46 Recurrent laryngeal neuropathy, resulting in laryngeal collapse has been recognised as a
47 performance-limiting disease process in horses since the 1800s.²³ The neuropathy is likely
48 to have a genetic basis however the precise aetiology remains uncertain.^{18,24-26} It is caused
49 by a progressive distal axonopathy and has historically been thought to affect multiple

50 nerves in the body but with the left recurrent laryngeal nerve most severely affected.
51 However, recent histological evaluation of the recurrent laryngeal nerve and other nerves
52 has determined the degeneration to be more correctly termed a bilateral mononeuropathy
53 with the degeneration limited to the recurrent laryngeal nerve.²⁷ The prevalence of RLN
54 varies between breeds with larger breeds more commonly affected.^{28,29} In Thoroughbreds
55 the prevalence of RLN has been reported based on resting endoscopic findings to be
56 between 2.6-8%.³⁰ In heavy draught horse breeds a prevalence of up to 35% has been
57 reported.³¹

58

59 1.2 Equine Laryngeal Anatomy

60 The larynx in the horse consists of three single cartilages (cricoid, thyroid and epiglottic)
61 and the paired arytenoid cartilages (Figure 1).^{14,32}




62

63 Figure 1. Single cricoid, thyroid, and epiglottic cartilages and paired arytenoid cartilages
64 form a communicating channel between the pharynx and trachea. Adapted from Janicek et
65 al. 2008.

66

67 The cricoid and thyroid cartilage are both composed of hyaline cartilage with the epiglottis
68 being elastic cartilage. The arytenoids are a combination of cartilage types with the
69 muscular process being hyaline with the remainder being elastic. The cricoid cartilage is
70 signet ring shaped and articulates with the thyroid at the cricothyroid articulation. It also
71 articulates with each of the arytenoids at the cricoarytenoid joint which is a diarthrodial
72 saddle-shaped joint. This joint is located such that the arytenoids are situated on either side
73 and in front of the cricoid and partly medial to the thyroid cartilage. The arytenoids are
74 slightly pyramidal in form and have three processes: the muscular, the vocal and the
75 corniculate process.¹⁴ The cricoid cartilage has been found on computed tomographic
76 imaging to have notable conformational differences at the caudal edge in Thoroughbred
77 larynges.³³ These differences are also markedly evident during dissections of the equine
78 larynx. The CAD muscle is a strong fan shaped muscle that attaches to the apex of the
79 muscular process of the arytenoid. A cartilaginous ridge extends cranially from the apex of
80 the muscular process along a line parallel to the orientation of the CAD muscle and is
81 termed the arcuate crest (*crista arcuata*). The paired left and right CAD cover the dorsal
82 surface of the cricoid and each has two neuromuscular components.³⁴ Each muscle
83 originates from half of the caudal cricoid lamina including the median ridge and the fibres
84 converge into a tendon that inserts onto the muscular process of the arytenoid.¹⁴ The action
85 of the CAD muscle is to dilate the *rima glottidis* by rotating the arytenoid at the
86 cricoarytenoid joint into an abducted position. The recurrent laryngeal nerve innervates the
87 CAD muscle and this is the only abductor of the larynx. The recurrent laryngeal nerve also
88 innervates the cricoarytenoideus lateralis (CAL), the arytenoideus transversus and the
89 thyroarytenoideus muscle group (combined ventricularis and the vocalis muscles) (Figure
90 2).^{14,16} All of these muscles are associated with adduction of the larynx and are similarly
91 affected to the CAD when there is RLN.³⁵



92

93 Figure 2. Overlay of intrinsic laryngeal muscles that abduct and adduct the diameter of the
94 rima glottidis via contraction. Adapted from Janicek et al. 2008.

95

96 1.3 Respiratory physiology related to laryngeal dysfunction

97 The respiratory system is the limiting factor for athletic performance in horses.^{6,36,37} This
98 is due to the delivery of oxygen being the primary limiting factor to increases in VO_{2max}
99 during strenuous exercise.³⁸ The equine cardiovascular and muscular systems can transport
100 and utilise more oxygen than the lungs can supply.³⁶ As a result during strenuous exercise
101 normal horses develop hypoxaemia (<60 mmHg) that will negatively impact further
102 aerobic performance.³⁸ Any impairment of the equine respiratory system such as laryngeal
103 collapse caused by RLN, will compromise athletic performance. This has been
104 demonstrated clearly in exercising horses where transection of the recurrent laryngeal
105 nerve significantly increased respiratory impedance and worsened exercise-induced
106 hypoxemia.^{10,19} Horses with RLN cannot achieve maximal abduction of the affected
107 arytenoid cartilage, and as negative inspiratory pressure increases with exercise, leads to
108 progressive narrowing of the *rima glottidis* due to arytenoid collapse. This subsequently

109 leads to hypoxemia, hypercarbia and metabolic acidosis occurring more quickly in horses
110 affected with RLN compared to non-affected horses and results in musculoskeletal fatigue
111 and poor performance.^{22,39} However, research has shown that the currently performed LP
112 improves airflow and reduces inspiratory resistance but does not restore airway mechanics
113 or arterial blood gases to normal limits.^{10,19,22,40} Furthermore, one study found that the
114 performed LP diminished normal laryngeal protective mechanisms leading to airway
115 contamination.¹⁰

116

117 1.4 Aetiology and pathophysiology of RLN

118 Laryngeal dysfunction is a common equine clinical problem and a genetic basis is most
119 likely, however, in a majority of affected horses the precise aetiology is uncertain.⁴¹ As a
120 result, between 89-94% of cases of laryngeal hemiplegia of unknown aetiology are
121 attributed to idiopathic RLN.^{26,42} The cause of RLN been hypothesised to range from
122 mechanical stretching of the recurrent laryngeal nerve during neck movement, growth and
123 caudal movement of the heart during embryogenesis to environmental factors, including
124 toxins.¹⁶ Histologically, idiopathic RLN is characterised by distal degeneration of the
125 recurrent laryngeal nerve.^{27,35,43} However, other disorders can cause damage to the
126 recurrent laryngeal nerve and this has been previously reported to be the case for the
127 remaining 6-11% of horses presented with LH.^{26,42} These include guttural pouch mycosis,
128 perivascular injections of irritant drugs in the area of the recurrent laryngeal nerve, neck
129 trauma and neoplasia.²⁶ Of horses with a specifically identified cause of RLN more than
130 half of these cases were bilaterally affected.^{26,42} Regardless of the exact aetiology, the
131 result is neurogenic atrophy of the laryngeal musculature, which mechanically results in an
132 inability to effectively abduct the affected arytenoid.

133

134 1.5 Diagnosis of RLN

135 Recurrent laryngeal neuropathy results in neurogenic atrophy of the CAD and leads to an
136 inability to abduct the affected arytenoid effectively from the airway. The diagnosis of
137 RLN can be suspected on the basis of history and physical examination.⁴⁴ However, as
138 previously discussed, RLN and the subsequent CAD atrophy varies in severity. As a result,
139 there are differing effects on performance depending on the degree of airway obstruction
140 and the nature of the intended athletic function of the horse. This results in the disorder
141 having a range of effects on performance from career limiting to clinically insignificant
142 inspiratory noise. As such, advanced diagnostic measures have been developed to
143 accurately diagnose and classify all affected horses in an effort to target treatments more
144 effectively. Diagnostic tools that have been investigated in the evaluation of RLN in horses
145 include: standing endoscopy, dynamic endoscopy, laryngeal ultrasound, exercise
146 spirometry, sound analysis, electromyography, CT and MRI.^{19,45-50} The current gold
147 standard for diagnosis of RLN is considered to be an exercising (dynamic) endoscopic
148 examination, which may be performed either on a high-speed treadmill or “over ground”.⁵
149 The video-endoscopic images are recorded and can be played back frame by frame to
150 allow for accurate diagnosis and classification of the type and severity of upper airway
151 dysfunction present in any horse suspected to be suffering from RLN.^{47,51-53}

152 Several grading systems have been developed for standing endoscopic assessment of
153 laryngeal function.^{54,55} These grading systems categorise horses based on arytenoid
154 abduction function at rest in an effort to grade the severity of dysfunction and draw
155 parallels relating to the likely corresponding function during exercise. As a result, standing
156 endoscopic grading was developed to allow for consistency in reporting of this condition
157 and also to allow evaluation of treatment success. A seven-grade system has been

158 developed and is widely accepted for use during standing endoscopic examinations as
 159 proposed initially by the Havemeyer workshop group and international experts in 2003
 160 (table 1).⁵⁵

Grade	Description	Sub-grade
1	All arytenoid cartilage movements are synchronous and symmetrical and full arytenoid cartilage abduction can be achieved and maintained.	
2	Arytenoid cartilage movements are asynchronous and/or larynx is asymmetric at times but full arytenoid cartilage abduction can be achieved and maintained.	2.1 Transient asynchrony, flutter, or delayed movements are seen. 2.2 There is asymmetry of the rima glottidis much of the time due to reduced mobility of the affected arytenoid and vocal fold but there are occasions, typically after swallowing or nasal occlusion when full symmetrical abduction is achieved and maintained.
3	Arytenoid cartilage movements are asynchronous and/or asymmetric. Full arytenoid cartilage abduction cannot be achieved and maintained.	3.1 There is asymmetry of the rima glottidis much of the time due to reduced mobility of the arytenoid and vocal fold but there are occasions, typically after swallowing or nasal occlusion, when full symmetrical abduction is achieved but not maintained. 3.2 Obvious arytenoid abductor deficit and arytenoid asymmetry. Full abduction is never achieved. 3.3 Marked but not total arytenoid abductor deficit and asymmetry with little arytenoid movement. Full abduction is never achieved
4	Complete immobility of the arytenoid cartilage and vocal fold.	

161 Table 1. Havemeyer grading system of laryngeal function in the standing unsedated horse.
 162 This grading generally refers to the left arytenoid cartilage in reference to the right but can
 163 be applied to right sided dysfunction.

164

165 In Australia and New Zealand a five-grade scale (table 2) has been used historically but is
166 gradually being replaced with the aforementioned Havemeyer scale.⁵⁴

Grade	Description
1	All movements, both adduction and abduction are synchronised and symmetrical .
2	All major movements are symmetrical and a full range is achieved. Transient asynchrony , flutter or delayed opening may be seen.
3	Asymmetry of the rima glottidis at rest due to reduced motility by the left arytenoid cartilage and vocal fold. On occasions, typically after swallowing or during the nostril closure manoeuvre, full symmetrical abduction is achieved .
4	There is consistent asymmetry of the rima glottidis but with some residual active motility by the left arytenoid cartilage and vocal fold. Full abduction is not achieved at any stage .
5	True hemiplegia. There is obvious and consistent asymmetry of the rima glottidis with no residual active motility by the left arytenoid cartilage and vocal fold.

167 Table 2. Five-point grading system as per Lane 2004.

168

169 The use of these resting endoscopic grading systems have been shown to be subjective and
170 influenced by factors such as sedation, which nostril the examination is performed via and
171 the day of the examination.⁵⁶ Further studies have shown that the correlation between
172 resting grades and dynamic laryngeal collapse is not highly reliable.^{47,52,57,58} Laryngeal
173 ultrasound has been shown to have a higher sensitivity and specificity (90% and 98%
174 respectively) than resting upper airway endoscopy (80 and 81% respectively) in the
175 prediction of abnormal arytenoid movement determined during a treadmill upper airway
176 endoscopic examination.⁵⁹

177 As a result of the inaccuracy of using standing laryngeal grade as a predictor of laryngeal

178 collapse methods of performing dynamic examination of the upper respiratory tract have
 179 been developed and are considered the gold standard diagnostic technique. These
 180 examinations are commonly performed using a high-speed treadmill or more recently
 181 using an over ground endoscopy system. A grading system to use during these dynamically
 182 exercising examinations has been proposed by Rakestraw (table 3).⁶⁰ This system
 183 differentiates based on the degree of arytenoid collapse at exercise.

Grade	Description
A	Full abduction of the arytenoid during inspiration
B	Partial abduction of the affected arytenoid cartilage (between resting position and full abduction)
C	Abduction less than resting position, including collapse into the contralateral half of the rima glottidis during inspiration

184 Table 3. Grading system of laryngeal function as assessed during exercise. This grading
 185 generally refers to the left arytenoid cartilage in reference to the right but can be applied to
 186 right sided dysfunction.

187

188 1.6 Treatment options for RLN

189 Several treatment options are available for horses with RLN and which option is selected is
 190 often based on the nature of the presenting complaint, the age of, and the intended future
 191 use of the horse. For horses required to perform at maximal levels of performance such as
 192 racehorses, the surgical treatments available include a prosthetic laryngoplasty,
 193 ventriculectomy, ventriculocordectomy, re-innervation of the CAD muscle and partial
 194 arytenoidectomy. The most commonly selected procedure in horses that are required to
 195 work and race at maximal exercise capacity for distances greater than 800m is a prosthetic
 196 laryngoplasty.⁶¹ This is commonly combined with either a ventriculectomy or a

197 ventriculocordectomy which may be performed unilaterally or bilaterally to abolish vocal
198 fold collapse and reduce respiratory noise.^{1,4,62,63} Where noise is the predominant
199 complaint, such as in performance horses, then a ventriculectomy or a
200 ventriculocordectomy alone can be effective in reducing respiratory noise.^{40,62,63}
201 Neuromuscular pedicle grafts can be used to re-innervate the CAD muscle and are suitable
202 for any affected horse but used most commonly in young horses with grade 3 laryngeal
203 movement, where return to athletic function is not expected within 4 months of surgery.²⁰
204 Successful re-innervation of the CAD following neuromuscular pedicle grafts can take 6-
205 12 months and is not, as a result, always suitable for horses that are required to return to
206 athletic performance quickly. A partial arytenoidectomy is often used as the treatment
207 option for failed laryngoplasty surgeries or in cases of arytenoid chondritis causing
208 malformation of the arytenoid cartilage. This has been found to improve airflow dynamics
209 compared to an induced laryngeal hemiplegic state but not back to normal values and not
210 as significantly as a laryngoplasty.¹⁰

211

212 1.7 Current Laryngoplasty Techniques, Success Rates and Complications

213 *1.7.1 Laryngoplasty technique*

214 Treatment by laryngoplasty was first reported by Cadiot in 1893, who transcutaneously
215 sutured the paralysed arytenoid to the thyroid cartilage.⁶⁴ With remarkably little variation,
216 the technique described by Marks and colleagues in 1970 is still accepted as the treatment
217 of choice, despite the limited success and host of possible complications.⁶⁵ This technique
218 fundamentally places a prosthesis to replace the function of the atrophied CAD muscle.
219 Generally speaking, a suture material is placed from the cricoid to the muscular process of
220 the arytenoid and then tightened to achieve the desired degree of arytenoid abduction. The

221 arytenoid is then fixed in a static position.

222

223 *1.7.2 Success Rates*

224 The reported success rate of the modern laryngoplasty procedure is extremely varied and
225 ranges from 5% to 95%.^{1,2,66-68} Of interest, there has not been a marked improvement in
226 reported success rates over time.^{1,61,66,69,70} The remarkable variation in reported success
227 rates is due to the different criteria used to measure success and the intended use of the
228 horse. Thoroughbred racehorses have a lower success rate (48-66%) compared to breeds
229 not intended for racing (90-95%).^{1,2,67,69} Laryngoplasty in horses not intended to race, or to
230 race over short distances (<800m) will be more successful due to the lower intensity of
231 performance or reduced reliance on aerobic metabolism respectively required post-
232 surgery.⁶¹

233 The current prosthetic laryngoplasty is a commonly performed procedure that has
234 significant scope for improvement. Clearly, the success rate is strongly dependent on the
235 intended use of the horse but for maximal athletic performance the success rates are
236 relatively poor.^{1,2,61,67,70} Because of this scope for improvement an enormous number of
237 variations on the basic theme of a static laryngoplasty have been developed and
238 subsequently researched with none of them being uniformly embraced by the equine
239 surgical community.^{4,71-75}

240

241 *1.7.3 Complications*

242 Due to the static nature of the laryngoplasty procedure, the horse's larynx is permanently
243 affixed in a partially abducted position post-operatively. This position is a compromise
244 between the requirements of the larynx to be abducted for maximal airflow yet still being
245 able to function in preventing food contamination of the airway. The complications

246 associated with the laryngoplasty procedure are mostly caused as a result of this
247 compromise. Many of these complications can be related to either over or under abduction
248 of the statically abducted arytenoid.

249 A variety of complications have been attributed to over abduction and dysphagia as a result
250 although this is not always a direct linear relationship.^{61,68} Post-operatively, 9-16% of
251 horses that underwent a laryngoplasty procedure have been reported to have some degree
252 of nasal discharge in the immediate postoperative period.^{1,3} Coughing has been reported to
253 occur in 13% of draft breeds, in 18-33% of mixed breeds, and in 26-43% of racehorses
254 undergoing laryngoplasty.^{1,2,4,66,76,77} In some cases, coughing may solely be a manifestation
255 of over abduction of the arytenoid.⁷⁸ Given that the most common cause for post-operative
256 coughing is aspiration of feed material, most management procedures are aimed at
257 reducing this complication by reducing aspiration. Although marked dysphagia was
258 associated exclusively with high amounts of abduction in one article, other investigators do
259 not believe this association has a direct linear correlation.^{61,68} Rates of intraoperative target
260 abduction vary depending on the study and have been reported to be 50-90%.^{4,56,68}
261 Furthermore, one study reported that abduction above resting position did not improve
262 performance but increased the rate of complications.² It is commonly accepted that
263 laryngoplasty procedures result in airway contamination over normal or hemiplegic
264 states.¹⁰ When excessive abduction is observed post-operatively and combined with
265 significant coughing and dysphagia, a second surgery to remove, replace, or loosen the
266 prosthesis is often recommended.

267 Complications due to loss of, or under, abduction are mostly related to poor exercise
268 performance. In general, loss of abduction is a well-recognized phenomenon of the
269 currently performed static laryngoplasty procedure and occurs most commonly in the first
270 7 days.^{66,68} Although greater abduction has been associated with higher rates of

271 complications, it has also been associated with a greater likelihood to return to work and
272 improved performance.^{2,77} As a result, the optimal degree of abduction is difficult to
273 evaluate at the time of surgery and even more difficult to maintain post-operatively.
274 Furthermore the “ideal” degree of abduction is likely highly variable and will likely need
275 to be determined on a case-by-case basis. For example, for horses performing at
276 submaximal levels (e.g., jumpers, draft horses), the concern is more often with reduction in
277 noise and not necessarily maximal airflow. Hence, a laryngoplasty at a lower percentage of
278 maximal abduction may be sufficient for their purpose and may not have as many
279 postoperative complications. In contrast, racehorses require maximal airway dilation to
280 allow them to compete and, as a result, may require more aggressively abducted
281 laryngoplasty procedures but with a static procedure these will inevitably be associated
282 with much higher rates and severities of complications. Satisfactory abduction at 9 days
283 postoperatively was achieved in only 77% of horses undergoing laryngoplasty surgery,
284 with failures mostly attributable to suture cutting through the laryngeal cartilages.⁶⁶ These
285 failures occurred in two 2-year-olds and a 3-year-old, leading the authors to hypothesise
286 that the cartilage of young horses was weaker and more prone to failure compared with
287 older horses.⁶¹ This claim was refuted, however, in an *in vitro* study determining pull-
288 through forces that indicated no difference related to age.⁷⁹ Furthermore, the density of the
289 cricoid cartilage has been found to be unrelated to age, suggesting that laryngoplasty
290 failure is independent of this factor.⁷⁹ Of 200 laryngoplasty surgeries performed in one
291 study, 5% had repeated surgery to tighten or replace prostheses within 7 days
292 postoperatively.⁶⁸ In addition to this short-term loss of abduction, longer-term loss of
293 abduction is also a commonly reported. It is often extremely difficult to determine the
294 exact reason for this failure. Complications such as prosthesis or cartilage failure are two
295 commonly postulated reasons. Attempting efforts to determine the reason for these long-

296 term failures. Suggested factors include acute mechanical cartilage failure, cyclic cartilage
297 failure resulting in gradual prosthesis loosening, improper prosthesis placement resulting in
298 biomechanical disadvantage and any disease state rendering cartilage weaker than
299 normal.⁷⁷ Efforts to reduce acute mechanical pull-out using novel prosthesis systems have
300 been performed but have not gained widespread acceptance.^{75,80} Recurrent laryngeal
301 neurectomy to abolish any residual adductor muscle activity that may contribute to
302 continued cyclic forces acting on the prosthesis was not effective in improving
303 postoperative racing performance.⁷⁷ Improper placement of the prosthesis overly lateral on
304 the cricoid results in loss of mechanical advantage and can lead to decreased abduction.³³

305

306 Horses that have undergone a laryngoplasty have been shown to be at an increased risk of
307 suffering from exercise induced pulmonary haemorrhage post-operatively.⁸¹

308 Laryngoplasty failure due to persistence of an abnormal respiratory noise or poor
309 performance can be due to laryngoplasty failure in general or due to the development of
310 other forms of dynamic laryngeal collapse such as dorsal displacement of the soft palate.⁸²

311

312

313 1.8 Biomechanics of Laryngoplasty

314 The current traditional prosthetic laryngoplasty utilises a prosthetic material to replace the
315 compromised CAD muscle function of the larynx and so achieve arytenoid abduction,
316 allowing for effective airflow. However, whilst the basic premise of the laryngoplasty has
317 not changed, the surgical techniques currently employed to achieve this are extremely
318 varied (e.g. suture type, suture numbers, position) and have been associated with unreliable

319 results. These static surgical options focus on the abduction of the arytenoid to a
320 predetermined position and maintaining it in that position.

321 There are four central components to the laryngoplasty construct. These are; the arytenoid
322 cartilage, 2) the cricoid cartilage, 3) the cricoarytenoid articulation and 4) a prosthetic
323 suture/material. How these segments interact determines the effectiveness of obtaining and
324 maintaining effective arytenoid abduction. Recent research has focused on the interplay of
325 these central components and attempted to maximise the stability of the surgical construct.
326 Mechanical research of the laryngoplasty has historically focused on single cycle testing to
327 failure.^{79,80,83-85} Recently, cyclical models of laryngoplasty testing have been reported and
328 are likely a more critical evaluation of traditional and novel laryngoplasty techniques as
329 they test smaller repeated forces on the construct which is more comparable to the stresses
330 on the construct during breathing, coughing and swallowing.^{75,86}

331 The load applied to the cartilage-suture construct *in vivo* is an important factor required for
332 effective mechanical evaluation of a laryngoplasty construct. An *in vivo* study evaluated
333 the force required to achieve optimal arytenoid abduction, which was found to be
334 $27.6 \pm 7.5\text{N}$. During swallowing and coughing, the mean force on the suture increased by
335 $19.0 \pm 5.6\text{N}$ and $12.1 \pm 3.6\text{N}$, respectively.^{87,88} Additionally, these horses were instrumented
336 for 24hrs and it was found that the suture underwent cyclical loading due to swallowing at
337 a mean of 1152 times in that period, a rate of 0.8 times per minute. From this research, it
338 was estimated that the peak force on a laryngoplasty construct would be 46.6N. This
339 reported force to obtain abduction was much higher than the force reported to cause
340 maximal abduction in a previous study that was only 14.7N.⁸⁹ However, this was an *in*
341 *vitro* study on cadaveric larynges and the load may have been lower than *in vivo* due to the
342 absence of muscular function or different suture placement positioning.

343

344 *1.8.1 The arytenoid cartilage*

345 The arytenoid cartilage has historically been suspected to be a major source of abduction
346 loss. This suspicion has led to significant research focused on the muscular process and its
347 role in maintaining abduction.^{79,83-85} This has included evaluation of the effect of age,
348 placement site, implantation technique and various suture configurations.^{79,84,85,90} Most of
349 this research has been performed in single cycle to failure models and has uniformly been
350 associated with loads at failure that are much higher than those demonstrated to occur *in*
351 *vivo*. In one study, six different suture configurations in the muscular process of the
352 arytenoid were examined using mechanical testing.⁸⁵ It was concluded that sutures that
353 sufficiently engaged the spine of the muscular process alone or in conjunction with a
354 second suture were the most biomechanically stable. These results parallel research in dogs
355 that found the size of the hole for the suture or the suture size had no or little effect, but
356 that sutures incorporating the arcuate crest were biomechanically superior, overall.⁸³
357 Recently, transection of the CAD muscle immediately behind its insertion onto the
358 muscular process has been reported to allow access to debride the cricoarytenoid (CA)
359 joint.⁷⁴ Transection of the CAD at its insertion also allows for superior identification of the
360 muscular process and possibly for more accurate and consistent suture placement as a
361 result.

362 The method of suture placement into the arytenoid cartilage has historically not been
363 shown to be an important factor (e.g. tunnelling a hole with a hypodermic needle compared
364 to a swaged on needle).⁸⁴ However, the use of a conventional cutting needle compared to a
365 tapercut needle resulted in significantly lower peak loads at failure in a single cycle model
366 and resulted in significantly more distraction in a cyclical model.⁹³ This was thought to
367 result from the cutting needle creating a groove into which the suture propagated more
368 readily than when placed with the tapercut needle. Recently, a screw placed into the

369 arytenoid has been utilised as a point of anchorage in the arytenoid.⁷¹ This technique has
370 not been utilised widely, however it is thought to increase stability of the arytenoid
371 segment of the laryngoplasty construct. The use of such a suture anchor has been
372 demonstrated to reduce the load required to achieve effective arytenoid abduction by
373 approximately 50%.⁹¹ Regardless of the method of attachment to the arytenoid, based on
374 the cyclical testing that has been performed it appears that the arytenoid cartilage is
375 unlikely to be a major source of loss of abduction if appropriate attachment is achieved.⁹²

376

377 *1.8.2 The cricoid cartilage*

378 More recently, the cricoid cartilage has been identified as an important component that
379 may be a source of variability and potential laryngoplasty failure. Computed tomographic
380 imaging of the cricoid has found there to be notable conformational differences among
381 cricoid specimens from a group of Thoroughbred larynges.³³ Logically, this variability at
382 the caudal aspect of the cricoid cartilage may result in some variability in the ability of the
383 cricoid to maintain a suture in the laryngoplasty construct. Suture migration in the cricoid
384 was identified as the cause of 50% of short term excessive loss of abduction in when it
385 occurred in a series of 200 horses.⁶⁸

386 Various techniques associated with the cricoid cartilage have been proposed to reduce the
387 loss of abduction. These range from sawing the suture to ‘seat it’ prior to tying, placing the
388 sutures ‘into’ the dorsal notch when present, double loops around the caudal edge of the
389 cricoid and novel laryngoplasty systems involving cables and washers or anchors.^{75,80}

390

391 *1.8.3 The cricoarytenoid articulation*

392 The cricoarytenoid articulation (CA) is an important component of a laryngoplasty
393 construct. The distances from the longer corniculate process to the articulation and

394 subsequently to the shorter muscular process are important components of a lever arm. As
395 a result of this lever arm, small changes in the position of the muscular process will result
396 in proportionally much larger changes in the positioning of the corniculate process. For
397 example, a loss of 5mm between the arytenoid/suture/cricoid construct will lead to a 15-
398 20mm loss at the corniculate process and resultantly significant abduction loss.⁹³
399 Recently the effect of stabilising the CA by injecting polymethylmethacrylate into the joint
400 space was evaluated using a static airflow model.⁹³ It was found that stabilising the joint
401 with PMMA resisted collapse of the airway and reduced the force experienced by the
402 suture during maximal abduction. More recently, a surgical technique to promote ankylosis
403 of the CA has been published that resulted in decreased loss of abduction of the arytenoid
404 in the post-operative period.⁷⁴ Utilisation of a technique to ankylose the CA joint reduced
405 the forces on the laryngoplasty sutures and resulted in less loss of abduction post-
406 operatively and should be considered as a means to help reduce loss of arytenoid
407 abduction.^{74,93,94}

408

409 *1.8.4 The prosthetic suture/material*

410 Various prosthetic materials have been reported to successfully perform a laryngoplasty.
411 Materials reported are not limited to but range from catgut, wire, nylon, polyester,
412 polytetrafluoroethylene, ultra-high molecular weight polyethylene, to braided cable.⁶⁶⁻
413 ^{68,73,75,77,78,88,95,96} Many of these materials are much stronger than the necessary
414 requirements to obtain and maintain abduction. It is broadly accepted that a non-absorbable
415 material that is of sufficient size (e.g. #5 [7.0metric]) is very unlikely to itself fail
416 mechanically and cause of loss of abduction in an equine laryngoplasty construct. The
417 strength of these materials is so far greater than the loading seen in a laryngoplasty
418 construct *in vivo* that so long as a reasonable suture material is selected it will not be a

419 cause of laryngoplasty failure.⁹⁷ It has been found that the use of two sutures in the
420 construct is superior to a single strand.⁸⁵ This is likely due to increased cartilage stability
421 with two strands rather than any increased strength on the part of the suture. Additionally,
422 slightly different angles of the sutures have been suggested to increase the CA joint
423 stability *in vitro*.⁹⁸

424

425

426 1.9 Conclusions

427 The currently available laryngoplasty techniques are fundamentally based on achieving a
428 static partially abducted position of the arytenoid. This permanently abducted position is
429 inevitably a compromise between the two major functions of the larynx: airflow and
430 deglutition. As a procedure, it has numerous and varied complications generally associated
431 with under abduction and reduced airflow or over abduction and contamination of the
432 airway. These complications are mostly associated with the static nature of the
433 laryngoplasty. The inability to determine where the “ideal” degree of abduction is at the
434 time of surgery and the inability, regardless of technique, to reliably position the arytenoid
435 without loss of abduction are limitations of the current laryngoplasty technique. With these
436 points in mind the overarching goal of this research was to develop a laryngoplasty
437 procedure that would be able to modify the degree of abduction of the arytenoid after
438 surgery. The ability to modify the degree of arytenoid abduction post-operatively may
439 potentially allow for improved success rates and lower complication rates as a result. As
440 such, this project attempts to develop such a system for use in horses.

441

442 1.10 Project Aims and Hypotheses

443 The principle aim of this project is to *develop* and *evaluate* a dynamic laryngoplasty
444 system (DLPS) for use in horses.

445 The major hypotheses to be tested are:

- 446 1. The developed dynamic laryngoplasty system (DLPS) is able to produce and
447 maintain a variable degree of arytenoid abduction *in vitro*
- 448 2. *In vivo*, the DLPS will allow for controlled variation of the arytenoid position
449 post-operatively

450 To test these hypotheses the following key objectives were set, each forming major themes
451 of the project:

452 Objective I: Prototype conceptualisation, development and optimisation

- 453 a) Prototype conceptualisation and development
- 454 b) *In vitro* comparison of three techniques of prosthesis attachment to the
455 muscular process of the equine arytenoid cartilage

456 This objective involved the development of a variety of working concept systems using 3D
457 printed models. Each system was evaluated for functionality using cadaveric larynges with
458 modifications and variations made to develop the final DLPS prototype that could be used
459 to cause controlled alterations in arytenoid abduction. Once the DLPS had been developed
460 to a working version the suture loop in which the device would be placed was examined in
461 an effort to maximize the mechanical advantage of its positioning minimising the force
462 required to achieve arytenoid abduction. This involved comparing 3 methods of attachment
463 to the arytenoid cartilage and selecting the most mechanically advantageous for use in the
464 final DLPS system.

465 Objective II: *In vitro* evaluation of the developed DLPS

466 a) Mechanical testing of a prototype DLPS to cause functional shortening
467 of a suture loop

468 b) *In vitro* evaluation of the efficacy of a prototype DLPS to affect
469 arytenoid abduction using equine cadaveric larynges

470 c) Evaluation of a prototype DLPS *in vitro* using a static airflow model

471 This objective involved three stages of *in vitro* testing for the DLPS. The first step was
472 basic mechanical testing to establish performance under static load, cyclical and ramp
473 testing situations. Second, the prototype was evaluated using cadaveric larynges to
474 evaluate the ability to affect arytenoid abduction within the specific anatomy of cadaveric
475 equine larynges. Finally, the prototype was evaluated using a static airflow model to ensure
476 the device could maintain the previously demonstrated arytenoid abduction when under
477 pressures similar to those seen in exercising horses.

478 Objective III: Proof of concept study

479 a) *In vivo* evaluation of a prototype DLPS in horses

480 This third and final objective was to confirm the surgical deliverability of the DLPS and
481 evaluate the degree of surgical arytenoid abduction that could be achieved using the DLPS
482 at 7-days post-operatively.

483

484

PART II: PROTOTYPE CONCEPTUALISATION, DEVELOPMENT AND

485

OPTIMISATION

Chapter 2: Prototype development

486

487

488 2.1 Introduction


489 When considering the overarching goal of developing a device that could allow for
490 alteration in the degree of arytenoid abduction at a point postoperatively, a number of
491 factors were considered. To achieve this goal a device would need to be “activated” in
492 some way that would cause an effective change in the degree of abduction of the arytenoid.
493 When examining the four key components of a traditional laryngoplasty, namely the
494 cricoid, the arytenoid, the cricoarytenoideus joint and a suture loop, the portion that could
495 potentially be modified to achieve the above stated goal was considered to be the suture
496 loop element. The suture loop is a flexible component of the laryngoplasty and if this could
497 be functionally shortened at a point post-operatively then this would achieve the goal of
498 selective alteration of arytenoid abduction. The development of a prototype to achieve this
499 functional shortening is the subject of the remainder of this chapter.

500

501 2.2 Conceptualisation

502 To achieve the required functional shortening of the suture loop various options were
503 considered with a focus on developing a simple and robust method. A balloon placed
504 between the suture loops was considered as means to achieve this shortening. Such a
505 positioned balloon would cause the suture loop to diverge and shorten as a result, which
506 should cause alteration in the degree of arytenoid abduction (Figure 2.2.1).

507




508

509 Figure 2.2.1 Left view of the larynx with the left CAD muscle removed (top). A stylised
510 traditionally placed suture loop (middle) from the muscular process of the arytenoid (left)
511 to the dorsocaudal aspect of the cricoid (right). The conceptualised balloon location
512 between the suture loop that would result in functional shortening and increased arytenoid
513 abduction as a result (bottom).

514

515 However, maintaining the suture loop between the inflating balloon to cause the shortening
516 was considered to be a problem. To restrain the suture relative to the balloon two parallel
517 layers of a stiff material that would resist the expansion of the balloon and further direct
518 this expansion such that it would cause divergence of the previously parallel suture loop
519 was considered. The original prototype used two discs of plastic either side of a balloon
520 such that inflation caused the balloon to expand in a controlled fashion (Figure 2.2.2)
521




522
523 Figure 2.2.2 The original prototype used two parallel discs of plastic (side view – top left,
524 top view – top right) that constrained the balloon within the device (end on view non-
525 inflated state – bottom left and end on view inflated state – bottom right).

526

527 The developed device was then placed within the suture loop such that in a non-inflated
528 state it caused minimal interference with the suture loop but when inflated it caused the

529 suture loop to diverge and as a result cause functional shortening. The suture loop, where
530 in contact with the balloon, had a tube of stiff plastic placed over it to prevent the suture
531 from sliding past the expanding balloon during inflation. The diameter of the stiff plastic
532 tube was slightly less than the width between the plastic discs (Figure 2.2.3).
533



534
535 Figure 2.2.3 The original prototype demonstrating a suture loop with the stiff plastic tubing
536 in place over the suture where it is in contact with the balloon.


537
538 This original prototype was effective at causing an increase in arytenoid abduction when
539 inflated between a suture loop in a cadaveric larynx. However, this original device was
540 large and cumbersome and additional prototype designs were developed.

541
542 **2.3 Prototype versions**

543 Online computer-aided design (CAD) software (www.tinkercad.com) was utilised to create
544 precision drawings of potential models for evaluation. The models were then printed using
545 a 3D printer in a variety of different materials, the idea being to develop the original

546 concept device outlined above into a refined prototype for further evaluation. In total eight
547 different design options were developed and printed using 3D printer with three considered
548 options demonstrated in figure 2.3.1 below.

549



550

551 Figure 2.3.1 Three options developed using CAD software and printed using a 3D printer
552 for evaluation.

553

554 Four types of materials that are available for use in 3D printing were evaluated. These
555 included nylon, Avrylonitrile Butadiene Styrene (ABS), Polylactic acid (PLA) and
556 Polymax™ PLA. These materials are thermoplastics that are used in 3D printing and have
557 been used medical implants. The first three materials were found to be too soft and easily
558 deformed with little force and as such were not able to constrain the balloon as required to
559 achieve the required function. The Polymax™ PLA is significantly stiffer than the other
560 materials but quite brittle such that when the balloon inflated the pillars connecting the two
561 discs would break (Figure 2.3.2).




562

563 Figure 2.3.2 A polymax™ PLA 3D printed prototype showing the failure point during
564 evaluation with a balloon inserted and inflated.

565

566 The 3D printed versions were extremely useful in determining the dimensions of the
567 device that was most appropriate to fit the anatomic limitations of the equine larynx. A
568 material that was considerably stronger and stiffer than the 3D printed options was
569 required. Polyether ether ketone (PEEK) is a colourless organic thermoplastic polymer that
570 is used in engineering applications and also for non-metallic surgical implants. This
571 material is commonly engineered to specifications from a block of PEEK in small
572 prototypes or by liquid mould injection in larger batches. The final version based on
573 evaluation of the 3D models was selected and engineered from PEEK for further testing.
574 The selected version using CAD modelling is demonstrated in figure 2.3.3 below.




575

576 Figure 2.3.3 model selected for manufacturing from PEEK material for *in vitro* evaluation.

577

578 2.4 Prototype evaluations

579 The final selected version made from PEEK was tested in a small number of cadaveric
580 larynges to determine the general function of the device prior to further more stringent
581 evaluations. The PEEK, unlike the previously evaluated 3D printed materials, did not
582 deform or break with balloon inflation and resulted in effective increases in arytenoid
583 abduction when positioned between a suture loop (Figure 2.4.1).



584


585 Figure 2.4.1 Preliminary evaluation of the PEEK prototypes ability to cause increased
586 arytenoid abduction with balloon inflation (no inflation – top image and inflated to 29psi
587 using a pressure syringe – bottom image).

588

589

590 2.5 Cadaveric testing of deliverability / functionality

591 Using an entire equine cadaver, the deliverability and functionality of the developed
592 prototype was evaluated. Using a standard laryngoplasty surgical approach for access to
593 the dorsolateral aspect of the larynx the prototype was inserted (Figure 2.5.1).




594

595 Figure 2.5.1 Surgical approach to the dorsolateral aspect of the larynx demonstrating
596 effective deliverability of the prototype device in an equine cadaver.

597

598 Subsequently, an endoscope was placed via the right nostril to allow for visualisation of
599 the rima glottis. Inflation of the balloon component of the prototype resulted in increased
600 arytenoid abduction (Figure 2.5.2).



601

602 Figure 2.5.2 Videoendoscopic images of pre-inflation (left) and post-inflation (right) states
603 using the PEEK prototype selected for further evaluation.

604

605 2.6 Discussion

606 When considering the goal of developing a device that could allow for alteration in the
607 degree of arytenoid abduction at a point postoperatively a number of factors were
608 considered. To achieve this goal a device would need to be “activated” in some way that
609 would cause an effective change in the degree of abduction of the arytenoid. The suture
610 loop is a flexible component of the laryngoplasty and if this could be functionally
611 shortened at a point post-operatively then this would achieve the goal of selective
612 alteration of arytenoid abduction. With these considerations in mind we developed and
613 evaluated a variety of prototypes and different methods of attachment to the arytenoid
614 before the final version of the DLPS was selected for subsequent testing.

615

Chapter 3: *In vitro* comparison of 3 techniques of prosthesis attachment to the

616

muscular process of the equine arytenoid cartilage

617

618

Statement of authorship

Title of Paper	<i>In vitro</i> comparison of 3 techniques of prosthesis attachment to the muscular process of the equine arytenoid cartilage	
Publication Status	<input checked="" type="checkbox"/> Published <input type="checkbox"/> Submitted for Publication <input type="checkbox"/> Accepted for Publication <input type="checkbox"/> Unpublished and Unsubmitted work written in manuscript style	
Publication Details	Veterinary Surgery April 29 th 2017 [Epub ahead of print]	

619

Principal Author

Name of Principal Author	Benjamin J. Ahern	
Contribution to the Paper	Designed experiments (80%) Performed experiments (100%) Wrote the paper (100%) Performed statistical analyses (50%)	
Overall percentage (%)	90%	
Certification:	This paper reports on original research I conducted during the period of my Higher Degree by Research candidature and is not subject to any obligations or contractual agreements with a third party that would constrain its inclusion in this thesis. I am the primary author of this paper.	
Signature	Date	20/6/17

620

621 **Co-Author Contributions**

622 By signing the Statement of Authorship, each author certifies that:

- 623 i. the candidate’s stated contribution to the publication is accurate (as detailed
 624 above);
 625 ii. permission is granted for the candidate to include the publication in the thesis; and
 626 iii. the sum of all co-author contributions is equal to 100% less the candidate’s stated
 627 contribution.

Name of Co-Author	Andrew W. Van Eps		
Contribution to the Paper	Critically reviewed paper (50%)		
Signature		Date	20/6/17

628

Name of Co-Author	Raymond C. Boston		
Contribution to the Paper	Performed statistical analyses (50%)		
Signature		Date	20/6/17

629

Name of Co-Author	Samantha H. Franklin		
Contribution to the Paper	Designed experiments (20%) Critically reviewed paper (50%)		
Signature		Date	20/06/17

630

631 3.1 Abstract

632 **Objectives-** Biomechanical comparison of arytenoid abduction achieved using three
633 different methods (FASTak II suture anchor and 2 suture patterns) of prosthesis attachment
634 *in vitro* to determine which achieves the greatest abduction at various clinically relevant
635 loads.

636 **Study Design-** Experimental.

637 **Study population-** Cadaveric larynges from 10 Standardbred racehorses.

638 **Methods-** Each larynx was sequentially instrumented with all three options of arytenoid
639 suture attachment in random order and then underwent mechanical testing at varying loads.
640 Each construct was abducted at 5 N increments from 0 to 25 N and the left to right quotient
641 angle ratio (LRQ) measured from digital pictures acquired at each sequential increment.

642 **Results-** The FASTak II construct achieved significantly increased arytenoid abduction
643 (higher LRQ) than both of the suture patterns tested. The largest difference occurred at 5N.
644 There was no significant difference between the two suture constructs tested at any load
645 point.

646 **Conclusions-** Use of the FASTak II suture anchor resulted in a construct that was
647 biomechanically superior to the 2 suture patterns tested. This is likely due to the anchor
648 producing a greater moment of force around the cricoarytenoid joint compared to the
649 suture patterns.

650 **Clinical Relevance-** Use of the FASTak II anchor requires less suture load to achieve
651 arytenoid abduction *in vitro* and should occur similarly *in vivo*. This will reduce the load
652 on the laryngoplasty construct in general and may result in less abduction loss post-
653 operatively.

654 3.2 Introduction

655 Recurrent laryngeal neuropathy (RLN) is a common problem in horses. The prevalence
656 varies with breed with rates as high as 10% in Thoroughbreds and 42% in draft horses.^{26,31}
657 The general principle of the laryngoplasty technique has undergone remarkably little
658 variation since it was first described by Marks et al. in 1970 and is still considered to be the
659 treatment of choice for this condition in athletic horses.⁶⁵ Nevertheless, there is a high
660 incidence of complications, including complete failure of abduction due to acute construct
661 failure (3-11%) or gradual loss of abduction, which is reported to occur in nearly all cases
662 in the longer post-operative period.⁹⁹⁻¹⁰²

663 Numerous models of single cycle and more recently cyclical testing have attempted to
664 identify components of the laryngoplasty construct that can be improved in order to
665 achieve a rigidly stable degree of rima glottis abduction.^{84,90,92,103-105} Furthermore, multiple
666 novel prostheses that focus on reducing suture/cartilage failure have been developed and
667 evaluated since Marks first described the laryngoplasty.^{71,73,75,80,96,105} These all have
668 similar biomechanical fundamentals, being the placement of a prosthesis of some type
669 from the caudal cricoid to the muscular process tied to cause arytenoid abduction.¹⁰⁶ The
670 orientation and positioning of the prosthetic material at the caudal aspect of the cricoid
671 cartilage has been examined to evaluate which configuration or positioning achieves the
672 best biomechanical construct and hence arytenoid abduction.^{84,98,107,108} Many studies have
673 focused on different methods of anchoring the respective prosthesis to the muscular
674 process mostly in single cycle to failure types of testing.^{79,84,85} One study compared two
675 techniques for suture placement in the muscular process using single cycle testing and
676 found no significant differences between direct suture placement using a trocar needle and
677 through a predrilled hole.¹¹ Another, more recent study by Lechartier et al (2014),
678 examined the mechanical properties of three different anchoring tests in the muscular

679 process of the arytenoid and found that a single screw technique (Corkscrew[®] device,
680 Arthrex) was more stable than a double loop and at least as stable as a single loop of suture
681 in cyclical testing.²⁵ Additionally, the double loop was found to be the strongest, followed
682 by the single screw then the single loop in single cycle to failure. It was concluded that the
683 anchor used was a reasonable option to hold loads in the arytenoid without failure to a
684 similar level as the more commonly used suture materials.

685 The focus of the research we report here was to evaluate three different methods of
686 muscular process attachment in order to determine the most mechanically advantageous
687 method to achieve arytenoid abduction. We utilised a FASTak II[®] suture anchor with #2
688 Fiberwire[®] preloaded (Arthrex). This anchor is similar to the one used by Lechartier et al
689 but has a slightly narrower diameter. Specifically, we wanted to determine which of the
690 three constructs required the least amount of force to achieve clinically relevant arytenoid
691 abduction.

692 The aim of this study was to objectively assess the effect of 3 different methods of
693 arytenoid attachment, 2 suture patterns and one FASTak II anchor, on rima glottis area in
694 equine cadaveric laryngeal specimens. We hypothesized that the FASTak II anchor would
695 achieve greater arytenoid abduction than both of the suture patterns evaluated due to a
696 superior mechanical position on the lever arm (muscular process) of the arytenoid.
697 Furthermore we hypothesized that the more commonly recommended suture direction of
698 caudomedial to craniolateral¹⁰⁷ would result in a greater arytenoid abduction than a medial
699 to lateral directed suture selected to represent what may be the “least ideal” position
700 option.

701

702 3.3 Materials and methods

703 *3.3.1 Specimen preparation*

704 Larynges from 10 Standardbred horses aged 3-11 years euthanized for reasons other than
705 respiratory disease were collected and frozen at -20⁰C. Larynges were thawed in batches at
706 room temperature for 24 hours. The thyroid, cricoid, epiglottic, arytenoid cartilages and the
707 right cricoarytenoideus muscle were all that were retained for testing. All other soft tissue
708 including the left cricoarytenoideus dorsalis muscle was removed.

709

710 *3.3.2 Specimen positioning*

711 Each larynx was positioned in exactly the same way, in a customized cradle positioned
712 30cm from a digital camera (HC-V250 high definition digital camera, Panasonic, Osaka,
713 Japan) that was controlled remotely using generic wireless technology.^{84,98,107} A 10cm
714 ruler was affixed to the cradle in frame as a reference.

715

716 *3.3.3 Suture placement*

717 For each larynx, the right side was abducted routinely using suture material and fixed in an
718 abducted position for the remainder of the testing. Subsequently, the left side of each
719 larynx was instrumented with each of the three constructs in a random order. Both suture
720 constructs were placed using #5 Ethibond Excel (7 metric; V-37, Ethicon Inc, NJ)⁹² in
721 either a caudomedial to craniolateral or horizontal medial to lateral direction. The
722 FASTak[®] II (Arthrex) with preloaded #2 Fiberwire suture (AR-1324HF, Arthrex) was
723 placed in the arytenoid 10mm cranial to the insertion of the CAD muscle, as described
724 previously.²⁵ The free ends of the 6 cm long loops were then attached caudally,
725 immediately adjacent to the cricoid cartilage 1.5cm lateral to the midline, to a hand held
726 tensiometer (Transducer techniques, Temecula, CA) similar to previous reports.^{98,107,109}

727

728 *3.3.4 Mechanical testing*

729 Each construct was sequentially loaded from 0 to 25N at 5N increments with digital
730 images acquired at each point. The tested construct was then removed and replaced by the
731 next construct and repeated until all were tested.

732

733 *3.3.5 Left to Right Quotient angle ratio (LRQ)*

734 Arytenoid LRQ was measured and calculated, as described previously, from each
735 photograph by one observer (B.A) using a soft-ware package (Image J, Bethesda,
736 USA).^{51,110} In brief, a line was drawn from the ventral to the dorsal aspect of the rima
737 glottis and then extended by one third to give a point that was used to measure the left (L°)
738 and right (R°) arytenoid angles. The LRQ was calculated by L° divided by R° .

739

740 *3.3.6 Statistical analysis*

741 Data were checked for normality and homogeneity of variance using D'Agostino's SK test,
742 '90, and Levene's, '60, Robust test for the equality of variances between groups. Data was
743 modelled using mixed effects regression models with the outcome 'LRQ' and predictor
744 variables 'load' and 'construct'. Wald statistics were used to indicate significant terms in
745 the mixed effects model and a chi-square test was used to confirm the significance of the
746 random effect. A p-value of 0.05 was used to assign statistical significance throughout.


747

748 *3.4 Results*

749 At zero load, there was no significant difference in LRQ between the three constructs
750 ($p=0.7$) (Figure 1.1). The FASTak II construct produced significantly more abduction
751 (higher LRQ) compared to both the suture constructs at all loads above zero with the

752 difference being largest at 5N ($p < 0.02$). There were no significant differences between the
753 two suture constructs at any load throughout the study ($p > 0.05$).

754



755

756 **Figure 1.1: Load versus resultant LRQ for each construct.** Stars denote significant
757 differences between FASTak II and suture constructs ($p < 0.05$). (FASTak was the FASTak
758 construct, M->L was the medial to lateral suture placement and CdM->CrL was the
759 caudomedial to craniolateral suture placement)

760

761

762 3.5 Discussion

763 The objective of this study was to determine which of the three prosthesis attachment
764 techniques evaluated produced the superior mechanical construct. Specifically, we

765 attempted to determine which construct produced the greatest arytenoid abduction at the
766 lowest load. We proved one hypothesis that the FASTak II anchor would produce the
767 highest LRQ and disproved our second hypothesis that the more commonly recommended
768 caudomedial to craniolateral suture placement would be superior to a medial to lateral
769 angled suture in the arytenoid.

770 The FASTak II anchor provides a point of attachment for the suture material that is
771 abaxially located in the muscular process of the arytenoid as compared to the location of
772 the suture patterns. Such positioning results in less force being required to abduct the
773 arytenoid because of the effect of the lever arm created by the cricoid, arytenoid and
774 cricoarytenoideus articulation.³⁰ This mechanically superior positioning coupled with the
775 previously reported comparable overall holding strength of a similar type of anchor
776 compared to suture constructs and ease of placement of the anchor (requires less dissection
777 in clinical cases) makes its use to attach suture to the muscular process very attractive. *In*
778 *vivo*, the use of the anchor should result in less force needing to be applied to the suture
779 material to achieve the desired degree of arytenoid abduction and result in a reduced load
780 on the construct in general. We hypothesise that this should lead to a reduced loss of
781 abduction due to cartilage or suture failure.

782 The loads used in this study were similar to those previously reported when evaluating the
783 cricoid cartilage component of the construct.^{88,107} Whilst, the lower loads (5N) we reported
784 to achieve abduction in cadaveric larynges may not transfer directly to the *in vivo* situation,
785 the differences seen between the anchor and the suture techniques persisted to relatively
786 high *in vitro* loads of 25N. This is not dissimilar to the load of 27.6N that has been
787 reported to be required to achieve clinically relevant arytenoid abduction, *in vivo*.⁸⁸ It is
788 reasonable to conclude, based on the findings of this study, that using the FASTak II
789 anchor *in vivo* may result in a significant reduction in the load required to achieve

790 clinically relevant abduction. This may then result in less clinical abduction failure if there
791 is less load on the prosthesis.

792 Gradual loss of arytenoid abduction in the post-operative period occurs in most
793 laryngoplasty procedures.⁹⁹ Given this common complication, techniques have been
794 developed such as mechanical arthrodesis of the cricoarytenoid joint which has been
795 shown to result in less abduction loss post-operatively⁷⁴ Other techniques to stabilize the
796 cricoarytenoid joint have also been reported using laser facilitated surgery or injection of
797 polymethylmethacrylate.^{93,94} These techniques focus on destroying the cricoarytenoid
798 joint which is still an option when using an anchor such as the FASTak II and indeed
799 combining the two may result in an even more stable laryngoplasty construct, although this
800 needs to be further evaluated.

801 We tested the constructs similar to previously reported models of *in vitro* evaluation of
802 arytenoid abduction rather than mount the constructs on a servo hydraulic testing system.
803 This allowed for the angle of suture distraction to be controlled to very accurately
804 represent the *in vivo* positioning, which would not have been as possible on a servo
805 hydraulic testing system. Also, we chose to test each of the 3 constructs on each of the
806 larynges to minimize variability in the testing system to allow for a clear understanding of
807 changing the single variable of how the suture was attached to the arytenoid and what
808 effect this had on arytenoid abduction. Finally, we measured the degree of abduction using
809 LRQ rather than cross sectional area (CSA) as this has previously been shown to be a more
810 accurate measurement tool *in vitro* compared to CSA.¹¹⁰

811 There was no difference between the 2 suture patterns tested. Retrospectively this is not
812 surprising as the bites across the arytenoid, whilst in a different plane, still go across the
813 body of the arytenoid and the summative effect of the suture loop through the arytenoid
814 results, mechanically speaking, in the distraction force coming from the middle of the body

815 of the arytenoid. As a result, there was no difference between the two patterns in the ability
816 to achieve arytenoid abduction. Clinically this means that the more important point during
817 suture placement is achieving a secure bite with the suture and the direction that the suture
818 is placed across the arytenoid is not important with regards to the load required for
819 abduction.

820 Comparison between 3 different techniques of prosthesis attachment to the muscular
821 process of the equine arytenoid cartilage found there to be significant differences in the
822 load required to achieve arytenoid abduction.²⁵ In our study, we found that using an
823 abaxially located anchor such as the FASTak II (Arthrex) resulted in a construct that
824 achieved abduction whilst requiring the least load. Use of this, or similar, suture anchors
825 should clinically result in it being easier to obtain the desired degree of intra-operative
826 arytenoid abduction and result in less initial and ongoing load on the construct. This
827 reduction in required load should result in a more stable laryngoplasty construct *in vivo*
828 with less acute short term and gradual longer term loss of arytenoid abduction.

830 **Chapter 4: Mechanical testing of a prototype dynamic laryngoplasty system (DLPS)**

831

832

Statement of authorship

Title of Paper	Mechanical testing of a prototype dynamic laryngoplasty system (DLPS)
Publication Status	<input type="checkbox"/> Published <input checked="" type="checkbox"/> Submitted for Publication <input type="checkbox"/> Accepted for Publication <input type="checkbox"/> Unpublished and Unsubmitted work written in manuscript style
Publication Details	Submitted to Veterinary Surgery June 2017

833

Principal Author

Name of Principal Author	Benjamin J. Ahern		
Contribution to the Paper	Designed experiments (80%) Performed experiments (100%) Wrote the paper (100%) Performed statistical analyses (100%)		
Overall percentage (%)	90%		
Certification:	This paper reports on original research I conducted during the period of my Higher Degree by Research candidature and is not subject to any obligations or contractual agreements with a third party that would constrain its inclusion in this thesis. I am the primary author of this paper.		
Signature		Date	20/6/17

834

835 **Co-Author Contributions**

836 By signing the Statement of Authorship, each author certifies that:

- 837 i. the candidate’s stated contribution to the publication is accurate (as detailed
 838 above);
- 839 ii. permission is granted for the candidate in include the publication in the thesis; and
- 840 iii. the sum of all co-author contributions is equal to 100% less the candidate’s stated
 841 contribution.

Name of Co-Author	Andrew W. Van Eps		
Contribution to the Paper	Critically reviewed paper (50%)		
Signature		Date	20/6/17

842

Name of Co-Author	Samantha H. Franklin		
Contribution to the Paper	Designed experiments (20%) Critically reviewed paper (50%)		
Signature		Date	20/06/17

843

844 4.1 Abstract

845 **Objectives-** *In vitro* biomechanical evaluation of a prototype dynamic laryngoplasty
846 system (DLPS).

847 **Study Design-** Experimental.

848 **Study units-** Ten prototype DLPS constructs.

849 **Methods-** Ten DLPS constructs were evaluated using an Instron mechanical testing
850 system. This included sequential testing in 3 stages to assess 1) the amount of distraction
851 achieved by DLPS activation at a static 10N load, 2) the response to cyclical testing from
852 10 to 15N and 3) single cycle ramp to 100N.

853 **Results-** The DLPS prototype was able to cause 7.11 ± 0.14 mm shortening of a suture loop
854 while under a static 10N load. During cyclical testing, no acute failures occurred and
855 overall 0.16 ± 0.03 mm of construct lengthening was recorded. Nine of the 10 constructs
856 completed a single cycle ramp loading to 100N without failure, the remaining one device
857 failed at 38.6N.

858 **Conclusions-** The prototype was found to be able to cause an approximately 12%
859 functional shortening of the suture loop and be able to withstand short term cyclical
860 loading. Nine of the 10 DLPS prototypes withstood ramp loading considerably above that
861 reported for *in vivo* loading on laryngoplasty sutures. Overall, the DLPS performed
862 sufficiently to justify further evaluation both *in vitro* and *in vivo*.

863 **Clinical Relevance-** The potential to modify the degree of arytenoid abduction post-
864 laryngoplasty may be a useful tool for equine surgeons considering loss of abduction post-
865 operatively is currently a common complication.


866

867 4.2 Introduction

868 Recurrent laryngeal neuropathy (RLN) is a common problem in horses. The prevalence
869 varies with breed, with rates as high as 10% in Thoroughbreds and 42% in draft horses.^{26,31}
870 The laryngoplasty (LP) technique described by Marks *et al.* in 1970 is currently the
871 treatment of choice for RLN in racehorses.⁶⁵ Complications following LP in horses are
872 many and varied and have been reported extensively.^{99,102} With the current LP technique, it
873 is a challenge during surgery to achieve the “ideal” degree of abduction to maximise
874 respiratory function whilst avoiding complications associated with this static position of
875 the arytenoid abduction. The basic premise of laryngoplasty is the use of a prosthetic
876 material to pull the arytenoid into abduction and maintain it statically in that position. This
877 underlying principle has not changed but there have been multiple variations developed
878 and evaluated.^{71,73,75,80,96,105} All of these LP system variations have been aimed at
879 attempting to maximise the stability of the static LP construct (i.e. arytenoid abduction).
880 The focus of the research we report here was to evaluate a prototype dynamic
881 laryngoplasty system (DLPS) *in vitro*. This DLPS was developed with the goal of being
882 able to selectively alter the degree of arytenoid abduction in the horse after surgery. This
883 device could have a number of advantages compared with the traditional LP. It could be
884 used to optimise arytenoid cartilage positioning in the immediate post-operative period.
885 Alternatively, it could be used to allow for correction of the gradual loss of abduction that
886 occurs post-operatively.¹¹¹ Finally, it might allow the arytenoid to be maintained in a
887 relatively adducted position at rest and be altered, to a maximally abducted position, when
888 peak airflow is required during exercise. Overall, an option to alter the degree of abduction
889 post-operatively may lead to reduced complications and potentially allow for improved
890 respiratory function during maximal exercise.

891 The developed DLPS prototype allows for shortening of a traditional laryngoplasty suture
892 loop by means of a balloon constrained within a custom designed polyether ether ketone
893 (PEEK) device (Figure 1).

894



895

896 Figure 1. Diagram form of how the prototype functions by inflation of the balloon (red)
897 between the 6cm long suture loop (blue) causing shortening as a result (functional
898 shortening= $6\text{cm}-X\text{cm}$). Black circles indicate points of attachment to mechanical testing
899 machine.

900

901

902 The device is designed to have a minimal profile and dimensions to suit the anatomic site
903 of placement: specifically, to fit within the space bounded by the caudal aspect of the
904 cricoid and the muscular process in a fully abducted position and from the sagittal ridge of
905 the cricoid to the wing of the thyroid cartilage. The DLPS can be inflated or deflated using
906 saline injected via an attached catheter that could eventually be attached to a subcutaneous
907 injection port allowing for minimally invasive post-operative alteration of arytenoid
908 abduction.

909 Prior to further testing of the DLPS prototype we wanted to determine its performance
910 using a mechanical testing unit. Our aims were to 1) determine the degree of construct
911 shortening that was possible using the DLPS, 2) evaluate the DLPS during cyclical loading
912 and 3) evaluate the DLPS during a single cycle to failure.


913 We hypothesised that the DLPS would 1) be able to effectively shorten the LP suture
914 construct (greater than 10% shortening of the suture loop), 2) maintain construct
915 shortening during cyclical testing (less than 1% increase in suture loop whilst the device is
916 activated) and 3) not fail during single cycle ramp testing.

917

918 4.3 Materials and Methods

919 Ten DLPS constructs were evaluated. All testing was performed using a servohydraulic
920 testing machine (Instron, Norwood, MA) linked to a data acquisition program
921 (LabChart™). For each test a new single strand of #2 Ethibond Excel ([5 metric] Ethicon
922 Inc, NJ) was used to form a 6cm loop (total suture length 12cm) which was passed through
923 2 metal eyelets rigidly affixed to the loading arms of the mechanical testing machine and
924 tied using standard technique to mimic a laryngoplasty suture loop. The selected DLPS
925 prototype was then instrumented in the 6cm loop and connected to an adjustable pressure

926 syringe (Blue Diamond™ Merit Medical) (Figure 2). Each DLPS construct was
927 sequentially tested in 3 stages; 1) static load-distraction, 2) cyclical testing and 3) single
928 cycle ramp to 100N.



929
930 Figure 2. Picture on left demonstrates construct positioning for testing and the PEEK
931 component of the DLPS in schematic form on the right.

932

933

934 *4.3.1 Static load – distraction testing*

935 Each DLPS construct was loaded to 10N and maintained at this load. The loss of
936 distraction (construct shortening) required to maintain the target 10N load caused during
937 sequential DLPS activation at 10psi increments to a maximum of 60psi as measured using
938 the adjustable pressure syringe were recorded.

939

940 *4.3.2 Cyclical testing*

941 With the DLPS activated at 50psi the load on the construct was cycled from 10 to 15 N at a
942 rate of 1 cycle per 1 second (1Hz) for 30 minutes (total 1800 cycles). The distraction that
943 occurred over the duration of this testing was recorded.

944

945 *4.3.3 Single cycle testing*

946 With the DLPS activated at 50psi the load was ramped to failure or 100N load (whichever
947 occurred first) at a rate of 0.83mm/s (50mm/min). From the generated load-distraction
948 curves, the load at failure (N) and stiffness (N/mm) were calculated for each construct.

949

950 All data is reported as mean \pm SEM throughout unless otherwise stated.


951

952

953 **4.4 Results**

954 *4.4.1 Static load – distraction testing*

955 All constructs completed testing without failure at the target load of 10N. The DLPS
956 caused a maximal shortening of the construct length of 7.11 ± 0.14 mm (Figure 3). This
957 equates to an effective 11.85% shortening of the 60mm long suture loop by maximal
958 activation of the DLPS. Further pressure increases were not possible due to the suture
959 material disengaging with the DLPS device or prolapsing off the DLPS balloon around the
960 suture.



961

962 Figure 3. Mean (+/- SEM) Distraction achieved during static load testing of 10 DLPS
 963 constructs at 10psi increments.

964

965 *4.4.2 Cyclical testing*

966 All constructs completed testing without failure. Over the 1800 cycles (30 minutes at 1Hz)
 967 there was an average increase of 0.16 ± 0.03 mm in construct length. The minimum and
 968 maximum load during testing was tightly controlled and was on average 9.82 ± 0.10 N and
 969 15.37 ± 0.28 N respectively.

970

971 *4.4.3 Single cycle testing*

972 Nine of the 10 DLPS constructs were loaded to 100N without failure and the testing was
 973 stopped due to load cell restrictions at that point. The stiffness for these 9 constructs was

974 11.35±0.63N/mm. The remaining single DLPS construct failed due to balloon rupture at
975 38.6N and most likely occurred due to the balloon pinching against the DLPS implant.

976

977

978 4.5 Discussion

979 We evaluated a novel DLPS *in vitro* using a series of mechanical tests to determine the
980 performance of this device in a simulated equine laryngoplasty suture loop. The DLPS was
981 able to cause shortening of the suture loop, withstand cyclical loading for 180 cycles and 9
982 of the 10 DLPS withstood 100N of load without failure. Based on this *in vitro* evaluation
983 further evaluation of the DLPS is warranted.

984

985 Our first goal was to determine what degree of shortening was possible using a suture loop
986 similar to a laryngoplasty construct *in vivo* using the DLPS. A 6cm loop of suture was
987 selected based on previous measurements of 10 adult equine cadaveric larynges which had
988 an average cricoid length at the dorsal midline of 5.3±0.7cm resulting in a laryngoplasty
989 suture loop length of approximately 6cm (Ahern, unpublished data). The selection of a
990 static force of 10N to test the degree of distraction that the DLPS could generate was based
991 on previous *in vivo* and *in vitro* work.^{88,89,112,113} The force on the laryngoplasty suture *in*
992 *vivo* when placed with the animal under general anaesthesia has been reported to be
993 27.6±7.5N.⁸⁸ However, recently during standing laryngoplasty the force required to obtain
994 abduction was subjectively lower in comparison.^{72,88} *In vitro*, much lower force (14.7N in
995 one study) has been reported to be required to achieve arytenoid abduction.⁸⁹ These
996 reported forces were measured using a traditional laryngoplasty suture placement through
997 the muscular process. The use of a suture anchor to position the point of distraction in a
998 mechanically superior position (more abaxially) will likely result in less force being

999 required to achieve effective abduction and, as a result, 10N was selected for this testing.¹¹³
1000 Based on these parameters the DLPS was able to cause 7.11mm of shortening, or almost
1001 12% reduction of the overall length of the construct.

1002

1003 The second goal was to evaluate the DLPS prototype during cyclical loading. The cyclic
1004 load was from 10 to 15 N at 1Hz. This rate of 1Hz was selected to ensure the Instron
1005 machine maintained a high level of accuracy at these relatively low loads. Using this
1006 cyclical testing for a period of 1800 cycles was completed successfully with a very small
1007 amount of total distraction (0.16mm or 0.26% of overall length). This number of cycles
1008 was similar to previously reported for *in vitro* laryngoplasty testing with the rate of loading
1009 slightly lower.⁷⁵ Laryngoplasty sutures have been shown to undergo loading a mean of
1010 1152 times in a 24 hour period.⁸⁸ As a result, the 1800 cycles used for this *in vitro* testing
1011 equates to slightly more than 1.5 days of cyclical testing seen *in vivo*. Using this *in vitro*
1012 model of testing the prototype was able to withstand cyclical loading sufficiently in the
1013 short term to justify further research.

1014

1015 The third and final goal was to evaluate the prototype during a single cycle test to a 100N
1016 load which is a considerably higher load that is likely to occur *in vivo* at any point.⁸⁸ One
1017 prototype failed at 38.6N and this appeared to be due to pinching of the balloon component
1018 of the DLPS against the PEEK. Smoothing of the PEEK portion of the device for mild
1019 manufacturing blemishes will likely resolve this problem. Another factor to consider is that
1020 using the DLPS prototype, the *in vivo* maximal load may not be as high as the previously
1021 reported 46.6N (recorded during induced swallowing) due to differences in the way the
1022 laryngoplasty was performed between these studies. Specifically, the use of an anchor for
1023 the arytenoid attachment has been shown to reduce the force required to achieve abduction

1024 by 50% compared to a traditional suture placement.⁹¹ Following on from this reduced load
1025 to achieve abduction it is possible that the peak load may be lower than the reported 46.6N.
1026 If the peak load is indeed lower than the 46.6N as a result of using the anchor then the
1027 DLPS failure that occurred at 38.6N is likely to be above the expected *in vivo* loading. As
1028 such, all 10 DLPS devices would have failed at loads above the expected *in vivo*
1029 conditions. However, the maximal *in vivo* load using an anchor as a component of a
1030 laryngoplasty is unknown and would be an interesting direction of future research.

1031

1032 Laryngoplasty techniques based on the procedure originally developed by Marks *et al* in
1033 1970 have undergone extensive *in vitro* and *in vivo* evaluation. The underlying principle of
1034 placing a prosthetic material(s) from the muscular process of the arytenoid to the caudal
1035 aspect of the cricoid has remained uniform throughout. Variations have been many and
1036 varied from originally Lycra to various types of suture material and even zip-ties.^{65,73,80,105}
1037 The laryngoplasty has been associated with success rates ranging from 45-70% in flat
1038 racehorses.^{57,67,77,114} The most common and significant complications associated with the
1039 procedure are loss of post-operative abduction and airway contamination (coughing /
1040 dysphagia).^{99,102} The development of a laryngoplasty system such as the DLPS evaluated
1041 in this research should as a minimum allow for post-operative surgical abduction
1042 modification / maintenance or ideally the ability to change the degree of arytenoid
1043 abduction longer term based on the specific exercise requirement of a horse at any
1044 particular time.

1045

1046 This research evaluated the mechanical function of a prototype DLPS *in vitro* to determine
1047 the device's ability to cause functional shortening of a simulated laryngoplasty construct
1048 and withstand physiologically relevant loading. The results of this research indicate that

1049 the further development and evaluation of the DLPS as a means to achieve dynamic
1050 arytenoid positioning is warranted.
1051

1058 **Co-Author Contributions**

1059 By signing the Statement of Authorship, each author certifies that:

- 1060 i. the candidate's stated contribution to the publication is accurate (as detailed
 1061 above);
 1062 ii. permission is granted for the candidate to include the publication in the thesis; and
 1063 iii. the sum of all co-author contributions is equal to 100% less the candidate's stated
 1064 contribution.

Name of Co-Author	Yee Wei Lim		
Contribution to the Paper	Performed experiments (50%) Wrote the paper (5%)		
Signature		Date	20/6/17

1065

Name of Co-Author	Andrew W. Van Eps		
Contribution to the Paper	Critically reviewed paper (50%)		
Signature		Date	20/6/17

1066

Name of Co-Author	Samantha H. Franklin		
Contribution to the Paper	Designed experiments (10%) Critically reviewed paper (50%)		
Signature		Date	20/6/17

1067

1068 5.1 Abstract

1069 **Objectives-** To evaluate the ability of a prototype dynamic laryngoplasty system (DLPS)
1070 to affect arytenoid abduction *in vitro*.

1071 **Study Design-** Experimental.

1072 **Study population-** Cadaveric larynges from 10 adult Standardbred and Thoroughbred
1073 racehorses.

1074 **Methods-** Dissected larynges were mounted and the right arytenoid maximally abducted
1075 for subsequent testing. A left sided laryngoplasty was performed using a single strand of
1076 #2Fiberwire and a FASTak®II suture anchor. Phase 1 of testing involved progressively
1077 shortening (tightening) the suture, without the DLPS device in place, in 1 mm increments
1078 and acquiring a digital image of the *rima glottidis* at each increment. Phase 1 was used to
1079 assess the amount of shortening required to achieve full arytenoid abduction and as a frame
1080 of reference for the results of subsequent testing. Phase 2 involved completing the
1081 laryngoplasty (tying the suture) at a target left to right quotient (LRQ) angle of 0.7 with the
1082 DLPS in place. Subsequently, digital images at 3 stages of DLPS activation (0, 25 and 50
1083 or maximal psi when 50 was not achieved) were obtained. All digital images were stored
1084 and analysed to generate LRQ angles as a measure of arytenoid abduction.

1085 **Results-** One larynx during dissection was found to have laryngeal dysplasia and was
1086 excluded. The remaining 9 larynges were anatomically normal and all aspects of testing
1087 were completed. In Phase 1, a total shortening of 25.89 ± 1.27 mm was possible and this
1088 increased the LRQ from 0.59 ± 0.02 to a maximum of 1.07 ± 0.12 . In Phase 2, activation of
1089 the DLPS caused the LRQ to increase from 0.70 ± 0.05 to a maximum of 0.97 ± 0.09 . This
1090 change in LRQ equated to 18.7mm of effective shortening based on Phase 1 results. The
1091 maximum psi before the balloon element of the DLPS prolapsed was 37.33 ± 5.96 .

1092 **Conclusions-** The DLPS was able to increase the degree of arytenoid abduction *in vitro*.
1093 This increase in LRQ was equivalent to 18.7mm of effective shortening of the
1094 laryngoplasty suture loop based on Phase 1 of the study.

1095 **Clinical relevance-** The DLPS may allow for adjustment of the degree of arytenoid
1096 abduction post-operatively. The results presented here support further evaluation of the
1097 device *in vitro* and ultimately *in vivo*.

1098 5.2 Introduction

1099 Recurrent laryngeal neuropathy (RLN) is a common problem in horses.^{26,31} The traditional
1100 laryngoplasty (LP) technique was first described by Marks *et al.* in 1970 and is still
1101 considered to be the treatment of choice for this condition in athletic horses.⁶⁵ There is a
1102 relatively high incidence of complications associated with this procedure, which have been
1103 associated either with under or over abduction of the surgically abducted arytenoid.⁹⁹⁻¹⁰²
1104 Furthermore, some degree of failure as measured by loss of arytenoid abduction has been
1105 reported to occur in nearly all cases.¹¹¹ The most commonly reported complications related
1106 to over abduction include coughing and/or aspiration.^{68,99,102}

1107 The surgical procedure of LP as described by Marks *et al.* (1970) has undergone
1108 remarkably little variation when compared to the modern reported variations. Overall the
1109 common principle of all traditional laryngoplasty techniques is to replace the action of the
1110 cricoarytenoideus (CAD) muscle to achieve arytenoid abduction using single or multiple
1111 prostheses. Over the years there has been considerable research into and variation of
1112 various components of the laryngoplasty procedure with the research focusing on
1113 achieving static abduction of the arytenoid with no or minimal loss of abduction in the
1114 post-operative period.^{71,73-75,80,96,105,112}

1115 The overarching objective of our research was to develop a means for performing a
1116 laryngoplasty with the ability to alter the degree of arytenoid abduction selectively after
1117 surgery. With this aim in mind we developed a dynamic laryngoplasty system (DLPS) that
1118 we have evaluated *in vitro* via mechanical testing. This testing found the DLPS when
1119 activated was able to produce 7.11mm (12%) of suture loop shortening at a static 10N
1120 load. Furthermore, the DLPS was able to withstand 100N ramp loading without failure in
1121 9/10 tests. Finally, cyclical testing resulted in 0.16mm (0.26%) of distraction loss during
1122 1800 cycles.¹¹⁵ Based on these encouraging mechanical testing results, the next step and

1123 the focus of this research was to evaluate the ability of the DLPS prototype to achieve
1124 changes in arytenoid abduction *in vitro* using cadaveric larynges.

1125 There were two aims of this study. The first aim (Phase 1) was to evaluate the relationship
1126 between shortening of the laryngoplasty suture (without the DLPS in place) and LRQ
1127 change, with the goal of assessing the amount of shortening required to achieve full
1128 arytenoid abduction and as a frame of reference for comparison with the results from the
1129 second phase of the study. The second aim (Phase 2) was to evaluate the relationship
1130 between DLPS activation and LRQ change.

1131 We hypothesised that activation of the DLPS would cause a change in LRQ of greater
1132 effect than the equivalent of LRQ change caused by 7.1mm of construct shortening.

1133

1134

1135 5.3 Materials and Methods

1136 5.3.1 Specimen preparation and positioning

1137 Larynges from 10 Standardbred and Thoroughbred horses aged 3-11 years euthanized for
1138 reasons other than respiratory disease were collected and frozen at -20⁰C. Larynges were
1139 then thawed at room temperature for 24 hours immediately prior to testing. The thyroid,
1140 cricoid, epiglottic and arytenoid cartilages and their intrinsic muscles were retained for
1141 testing, with the other soft tissue removed. The cricoid length at the dorsal midline was
1142 measured using callipers and recorded for each larynx. Each larynx was positioned in a
1143 standardised manner: mounted in a customized cradle as previously reported⁹⁸ and
1144 positioned 30 cm from a digital camera (HC-V250 high definition digital camera,
1145 Panasonic, Osaka, Japan) that was controlled remotely using generic wireless technology.
1146 A 10-cm ruler was affixed in the same plane as the laryngeal opening as a reference in the
1147 digital image.

1148

1149 *5.3.2 Laryngoplasty suture placement*

1150 For each larynx, the right arytenoid was maximally abducted and fixed in position for all
1151 testing as reported.^{91,116} The left side had a #2 Fiberwire suture (removed from the
1152 preloaded position in a FASTak[®]II (AR-1324HF, Arthrex)) placed through the cricoid
1153 cartilage 1.5cm lateral to the midline and 1.5cm from the caudal edge. For the arytenoid
1154 attachment the FASTak[®]II suture anchor was placed in the arytenoid 10mm cranial to the
1155 insertion of the CAD muscle as previously described.^{91,113} The suture was then threaded
1156 through the eyelet of the anchor from medial to lateral such that the two threads ends were
1157 in a relatively lateral position creating a single suture loop.

1158

1159 *5.3.3 Phase 1 testing – suture shortening*

1160 For Phase 1 testing, the ends of the suture at the mid-point (from cranial to caudal) of the
1161 cricoid cartilage were attached to the arms of a Vernier calliper to allow for progressive
1162 controlled construct shortening at 1 mm increments by opening the calliper arms (Figure
1163 1). Digital images were obtained at each 1mm of construct shortening to assess progressive
1164 arytenoid abduction until no further abduction could be achieved.

1165



1166

1167 Figure 1. Position of callipers to allow for progressive shortening of the laryngoplasty
1168 construct.

1169

1170 *5.3.4 Phase 2 testing – DLPS activation*

1171 Immediately following Phase 1 testing of each larynx, the suture was tied routinely with a
1172 surgeon’s knot and 4 single throws to the left arytenoid at an approximate LRQ of 0.7.
1173 Subsequently, the DLPS was inserted in position between the two suture threads. The
1174 associated 30cm long catheter with the attached injection port was located so that handling
1175 of the injection port did not alter the position of the larynx. Three states were tested;
1176 “inactivated” (no saline injection - 0 psi) and 2 levels of activation (25psi and 50 psi). The
1177 25 psi and 50 psi pressures of activation were achieved by injecting saline into the
1178 injection port and the pressures were selected based on the previous mechanical testing
1179 results.¹¹⁵ As previously reported, the injection pressure was measured using a pressure

1180 syringe (Blue Diamond™ Merit Medical).¹¹⁵ If a pressure of 50psi was not achieved the
1181 maximal pressure was recorded and the reason for failure to achieve 50psi recorded.
1182 Digital images were obtained at each of the 3 levels (Figure 2).



1183
1184 Figure 2. Larynx mounted for testing showing 0, 25 and 50 psi activation of the DLPS
1185 from left to right respectively.

1186

1187 *5.3.5 Left to Right Quotient angle ratio (LRQ)*

1188 Arytenoid LRQ was measured and calculated as previously described from each
1189 photograph by one observer (B.A.) using a soft-ware package (Image J, Bethesda,
1190 USA).^{51,110} In short, a line was drawn from the ventral to the dorsal aspect of the rima
1191 glottis and then extended by one third to give a point that was used to measure the left (L°)
1192 and right (R°) arytenoid angles. The LRQ was then calculated by dividing L° from R° .

1193

1194 *5.3.6 Statistical analysis*

1195 Multivariable logistic regressions using ordinary least squares were used to a) fit the LRQ
1196 to amount of laryngeal shortening (mm) and b) fit the LRQ to DLPS pressure (psi) for each
1197 larynx used. Predicted estimates of the observed values were produced and used to
1198 calculate the line of best fit with 95% confidence intervals. All analyses utilised a 5% two-


1199 tail probability point as the basis for rejection of null hypotheses of no difference from a
1200 zero value (slope). Stata version 14.1 was used for all analysis and data is reported as
1201 mean \pm SD. Graphs are presented with 95% confidence intervals.

1202

1203 5.4 Results

1204 During dissection one larynx was found to have abnormal anatomy consistent with
1205 laryngeal dysplasia and was excluded from testing. All remaining 9 larynges were
1206 anatomically normal and completed testing without problems associated with mounting,
1207 image acquisition or LRQ calculation. The 9 larynges had a dorsal cricoid length of
1208 52.28 ± 2.36 mm.

1209 For phase 1 of testing a total shortening of 25.89 ± 1.27 mm was achieved which resulted in
1210 the LRQ increasing from a baseline of 0.59 ± 0.02 to a maximum of 1.07 ± 0.12 . This was a
1211 mean increase in LRQ of 0.47 ± 0.12 . The linear regression for all data points produced a R^2
1212 value of 0.91 (Figure 3). A maximum of 25.89 ± 3.82 mm of suture shortening was possible
1213 before further shortening did not cause additional increases in LRQ.




1214

1215 Figure 3. Linear regression of progressive suture shortening and resultant LRQ. Data
 1216 reported as mean \pm SD with 95%CI.

1217

1218 For phase 2 of testing, the DLPS was instrumented to the left side of the larynx between
 1219 the two suture loops without complication in all cases. Activation of the DLPS resulted in
 1220 an increase in LRQ from 0.70 ± 0.05 (0 psi) to a maximum of 0.97 ± 0.09 ($p < 0.001$) (Figure
 1221 4). This change in LRQ equated to 18.7mm of effective shortening based on linear
 1222 regression of the phase 1 results. Eight of the 9 DLPS failed to reach the target of 50 psi
 1223 because in all cases the balloon component became overinflated and prolapsed from the
 1224 device after protruding from the rigid portion of the DLPS. Additional injections of saline
 1225 did not result in further increases in LRQ or pressure once the prolapse occurred. The
 1226 maximum psi for all prototypes tested was 37.33 ± 5.96 psi.

1227



1228

1229 Figure 4. Linear regression of activation pressure and resultant LRQ. Data reported as
 1230 mean \pm SD with 95%CI.

1231

1232

1233 5.5 Discussion

1234 We evaluated *in vitro* a novel DLPS that allowed for selective alteration of the degree of
 1235 arytenoid abduction using inflation via an injection port. This device has been developed
 1236 as a potential method that could be used to selectively alter the degree of arytenoid
 1237 abduction after laryngoplasty surgery. This option may be useful to optimise post-
 1238 operative arytenoid abduction and potentially reduce complications associated with
 1239 suboptimal (over or under) abduction.

1240 This *in vitro* evaluation was essential to confirm the deliverability of the device and
 1241 relative performance using cadaveric larynges. Previous mechanical testing evaluation of

1242 the DLPS found that the device could cause functional shortening of 7.11m of a suture
1243 loop under a static load of 10N. Furthermore, the device was able to withstand ramp to
1244 100N failure in 9/10 tests and had minimal displacement with cyclical testing.¹¹⁵ This
1245 research aimed to build on these earlier mechanical testing results by evaluating the DLPS
1246 using cadaveric larynges. This phase of evaluation of the DLPS was important to ensure
1247 the device could cause alteration in arytenoid position in normal cadaveric larynges.

1248 The 9 larynges used in this study were obtained from adult Thoroughbred and
1249 Standardbred horses with no visual evidence of laryngeal abnormalities. We elected to use
1250 LRQ as a means of evaluating change in arytenoid abduction similar to previous
1251 studies.^{51,74,94,110} We selected LRQ because as long as the camera position and laryngeal
1252 position are fixed and uniform, as was the case in this testing, then minor variations in the
1253 original position of the larynx or camera do not affect the results. A similar means of *in*
1254 *vitro* testing using LRQ has been previously reported.^{91,110} Cross sectional area of the rima
1255 glottis would have been an alternative method of measuring arytenoid abduction
1256 comparatively but based on previous research comparing the two methods there is no
1257 significant difference and due to the simplicity and robustness of LRQ measurements this
1258 was selected.⁵¹

1259 The first phase of this study was performed to assess the amount of shortening required to
1260 achieve full arytenoid abduction and serve as a frame of reference for the results of phase 2
1261 testing. During this phase 1, shortening of the suture loop using callipers without the DLPS
1262 in place, caused relatively consistent and linear ($R^2=0.91$) increases in LRQ up to between
1263 25-30 mm of shortening. At that maximal degree of shortening further efforts to shorten
1264 the loop did not cause additional increases in LRQ and represented the maximal range of
1265 suture shortening possible which was limited by the relative anatomic dimensions of the
1266 larynx.

1267 In the second phase of the study we evaluated the DLPS at three levels, based on the
1268 mechanical testing results to reflect what we considered to be baseline or inactivated
1269 (0psi), moderate activation (25 psi) and maximal activation (50 psi). We selected an
1270 inactivated target LRQ of 0.7 in an effort to represent a low to moderate level of arytenoid
1271 abduction that might represent the lower end of a spectrum of arytenoid abduction
1272 surgeons might aim for clinically when performing a laryngoplasty.^{4,56,68} As a result, a
1273 LRQ of 0.7 was selected to represent a level at which the DLPS might be used clinically to
1274 increase arytenoid abduction post-operatively. This study evaluated the DLPS ability to
1275 cause this increase in LRQ from 0.7 with 2 levels of activation.

1276 Activation by injection in the port was readily achieved using saline and caused significant
1277 increases in LRQ with increasing pressure. Using the linear regression model from Phase
1278 1, the increase in LRQ by maximal activation corresponded with 18.7mm of suture
1279 shortening. This was more than the 7.11mm of suture shortening found in the previous
1280 mechanical testing study when tested at a static load of 10N. The result of this study
1281 supported our hypothesis that activation of the DLPS would cause a change in LRQ of
1282 greater effect than the equivalent of LRQ change caused by 7.11mm of construct
1283 shortening. The degree of LRQ change and corresponding suture shortening was
1284 considerably higher than during the previous mechanical testing. This is due to the
1285 cadaveric nature of this research where there are relatively little forces restricting arytenoid
1286 abduction. In an *in vivo* situation the arytenoid would be subject to adduction forces seen
1287 with coughing, swallowing or negative airway pressures which may mean the DLPS used
1288 *in vivo* may be less able to achieve the increases in arytenoid abduction seen in this *in vitro*
1289 study, although this is unknown at this time.⁸⁸ However, due to the use of an anchor in the
1290 arytenoid which has been shown to reduce the load on the laryngoplasty suture by
1291 approximately 50% the exact effect of these forces is as yet undetermined.⁹¹ Before *in vivo*

1292 testing, the next step in evaluating the DLPS should involve further *in vitro* testing using
1293 an airflow model, similar to previously reported studies, to simulate the negative airway
1294 pressures seen *in vivo*.^{74,86,94}

1295 The balloon component of the DLPS was found to prolapse and not cause further increases
1296 in LRQ at pressures between 30-40 psi. This was due to the DLPS having produced
1297 maximal shortening of the suture and represents the maximal amount of construct
1298 shortening achievable *in vitro*. As a result, it may be useful *in vivo* to monitor the injection
1299 pressure, or, the endoscopic appearance and when there is a plateau of pressure or in
1300 arytenoid abduction, then this will likely represent the point of maximum performance of
1301 the DLPS. With regards to monitoring the pressure the effect of soft tissue surrounding the
1302 DLPS *in vivo* is as yet unknown and may potentially limit prolapse of the balloon element,
1303 which may alter the pressure required to achieve full activation. As a result, the
1304 combination of endoscopic and pressure monitoring in conjunction may be the most ideal.

1305 In conclusion, we found the prototype DLPS was able to effectively achieve significant
1306 increases in arytenoid abduction *in vitro*. We supported our hypothesis by finding the
1307 DLPS was able to cause arytenoid abduction equivalent to 18.7mm of shortening which
1308 was more than the 7.11mm found in previous mechanical testing research. These results
1309 support the further evaluation of this device with an overarching objective of trying to
1310 develop a clinically useful means of selectively altering the degree of arytenoid abduction
1311 post-operatively.

1318 **Co-Author Contributions**

1319 By signing the Statement of Authorship, each author certifies that:

- 1320 i. the candidate's stated contribution to the publication is accurate (as detailed
 1321 above);
 1322 ii. permission is granted for the candidate to include the publication in the thesis; and
 1323 iii. the sum of all co-author contributions is equal to 100% less the candidate's stated
 1324 contribution.

Name of Co-Author	Emily C. Lukas		
Contribution to the Paper	Performed experiments (20%) Wrote the paper (5%)		
Signature	_____	Date	20/6/17

1325

Name of Co-Author	Kimberly P. Lam		
Contribution to the Paper	Performed experiments (20%) Wrote the paper (5%)		
Signature	_____	Date	20/6/17

1326

Name of Co-Author	Emma LW. Wilkie		
Contribution to the Paper	Performed experiments (20%) Wrote the paper (5%)		
Signature	_____	Date	20/6/17

1327

Name of Co-Author	Francois-Rene Bertin		
Contribution to the Paper	Performed statistical analyses (75%)		
Signature	_____	Date	20/6/17

1328

Name of Co-Author	Andrew W. Van Eps		
Contribution to the Paper	Critically reviewed paper (50%)		
Signature	_____	Date	20/6/17

1329

Name of Co-Author	Samantha H. Franklin		
Contribution to the Paper	Designed experiments (20%) Critically reviewed paper (50%)		
Signature		Date	20/06/17

1330

1331 6.1 Abstract

1332 **Objectives-** Evaluation of a prototype dynamic laryngoplasty system (DLPS) *in vitro*
1333 using an static airflow model.

1334 **Study Design-** Experimental.

1335 **Study units-** Cadaveric larynges from 10 adult Standardbred and Thoroughbred horses.

1336 **Methods-** Dissected larynges were mounted within the testing system with the right
1337 arytenoid maximally abducted for all testing. A left-sided laryngoplasty using a single
1338 strand of #2Fiberwire and a FASTak[®]II suture anchor was performed. Each larynx was
1339 tested using a static airflow model in 2 phases. Immediately prior to testing of each larynx,
1340 the system was adjusted to produce a standard 55 L/s flow rate and a pre-laryngeal
1341 pressure of 12 mmHg whilst both arytenoids were maximally abducted. For phase 1 of
1342 testing the suture loop was progressively shortened (tightened), in 3 mm increments from 0
1343 mm to 30 mm and the larynx tested at each increment. In phase 2 the variable balloon
1344 portion of the DLPS was inserted and three stages of DLPS activation (inactivated [0], 25
1345 and maximal psi) were tested. Each test was a 5 second period of static airflow as outlined
1346 above. Translaryngeal impedance (TLI), left to right quotient angles (LRQ) and cross
1347 sectional areas (CSA) were calculated for each test. Data is reported as mean +/- SEM.

1348 **Results-** Activation of the DLPS caused increases in both CSA and LRQ ($p < 0.05$).
1349 Translaryngeal impedance was significantly reduced by suture tightening up to 6mm, but
1350 not by additional shortening ($p = 0.001$). In the second phase of the study, activation of the
1351 DLPS prototype caused a significant reduction in TLI from no activation (0 psi)
1352 ($0.43 \pm 0.08 \text{ mmHg/L/sec}$) to 25 psi ($0.16 \pm 0.04 \text{ mmHg/L/sec}$, $p < 0.001$) and a smaller but
1353 non-significant additional reduction ($0.13 \pm 0.03 \text{ mmHg/L/sec}$) at maximal activation.

1354 **Conclusions-** The prototype DLPS was able to cause significant reductions in TLI by
1355 activation from 0 to 25 psi and a further smaller non-significant reduction at maximal psi.

1356 **Clinical Relevance-** The DLPS prototype in this *in vitro* airflow system was shown to be
1357 able to achieve and maintain arytenoid abduction that was beneficial to airflow. Based on
1358 these results further evaluation *in vivo* is supported.

1359 6.2 Introduction

1360 Recurrent laryngeal neuropathy (RLN) is a common problem in horses.^{26,31} The currently
1361 recommended treatment of choice for this condition in athletic horses is a prosthetic
1362 laryngoplasty (LP) based on the technique originally described by Marks *et al* in
1363 1970.^{26,31,65} This LP technique fundamentally aims to produce static abduction of the
1364 arytenoid thereby preventing arytenoid cartilage collapse during exercise. Recent
1365 modifications of the LP have focused on different prosthesis materials, different methods
1366 to anchor to the cartilage, and evaluated different methods to fuse the cricoarytenoideus
1367 articulation.^{71,74,93,94,113} Overall, the reported success rate for LP surgery for racehorses has
1368 been reported to be in the range of 38-78%.¹⁰⁶

1369 Our group has aimed to develop a LP technique that allows for alteration of the degree of
1370 arytenoid abduction post-operatively to maximise efficacy and minimise complications.
1371 This would ideally allow for a more dynamic, or adjustable, degree of arytenoid abduction
1372 that could be customised to a particular horses' airway requirements. This effort to develop
1373 an adjustable LP is based on the fact that when a LP is performed the majority of horses
1374 will develop a loss of arytenoid abduction by 1-2 grades within the first 6 weeks.¹¹¹ This
1375 loss of abduction can be quite variable and presents a challenge to surgeons who are
1376 aiming for the target degree of arytenoid abduction that equates to 88% of the cross
1377 sectional area of the *rima glottidis* based on computational modelling of airflow.²¹ Based
1378 on previous *in vitro* testing by our group this suggested 88% CSA equates to an
1379 approximate LRQ of 0.7-0.75 (data not shown). To achieve these targets clinically it can
1380 be tempting to over-abduct the arytenoid at surgery and then rely on post-surgical
1381 abduction loss to occur and "settle" to the desired arytenoid position. However,
1382 complications such as coughing and aspiration pneumonia have been attributed to over
1383 abduction of the arytenoid.^{73,78,88,99,117} Additionally, some of these complications such as

1384 coughing have been found to put greater pressure on the prosthesis which can lead to either
1385 cartilage or LP failure.⁹⁹ Due to these considerations, the ability to alter the degree of
1386 abduction post-operatively to customise the degree of arytenoid abduction may provide a
1387 useful option for equine surgeons performing LPs.

1388 Previously, our group has developed a prototype dynamic laryngoplasty system (DLPS)
1389 and evaluated it to ensure the device was capable of withstanding reasonable loading
1390 conditions whilst mounted on a mechanical testing machine. That research found the
1391 device was able to produce 7.11mm of construct shortening at a constant load of 10N,
1392 which was selected to approximate loading expected *in vivo* based on previous research.
1393 Subsequently, the DLPS was evaluated *in vitro* using cadaveric larynges to determine the
1394 ability of the device to alter the degree of arytenoid abduction within the specific anatomy
1395 of the equine larynx. That research found the prototype was able to achieve 18.7mm of
1396 effective shortening and significantly increase the degree of arytenoid abduction as a
1397 result.

1398 The aim of this study was to evaluate the ability of the DLPS prototype to affect and
1399 maintain a reduction in translaryngeal impedance (TLI) using a static airflow model
1400 similar to previously reported systems, as a final step prior to *in vivo* testing.^{74,86,94,116}

1401 For this study, we had two hypotheses. Firstly (1), that activation of the DLPS would
1402 reduce TLI during airflow testing compared to no activation. Secondly (2), we
1403 hypothesised that activation of the DLPS would prevent dynamic collapse of the rima
1404 glottis during airflow testing.

1405

1406 6.3 Materials and Methods

1407 *6.3.1 Specimen preparation*

1408 Larynges and a segment of attached trachea from 10 Standardbred and Thoroughbred
1409 horses aged 3-11 years were collected and frozen at -20⁰C. The larynges were then thawed
1410 at room temperature for 24 hours immediately prior to testing. Once the larynges were
1411 confirmed to have grossly normal anatomy, the thyroid, cricoid, epiglottic, arytenoid
1412 cartilages, 2 tracheal rings and all intrinsic muscles were retained for testing, with all other
1413 soft tissue removed. The left cricoarytenoideus dorsalis (CAD) muscle was transected
1414 immediately caudal to its insertion on the muscular process of the arytenoid cartilage prior
1415 to testing.

1416

1417 *6.3.2 Suture placement*


1418 For each larynx, the right side was fixed in a maximally abducted position for all of the
1419 testing.^{91,116} As previously reported, for the left sided LP, #2 Fiberwire suture (Arthrex™)
1420 was passed using a trocar point half circle needle through the cricoid cartilage 1.5 cm
1421 lateral to the midline and 1.5 cm from the caudal edge.⁹¹ For the arytenoid attachment a
1422 FASTak®II (AR-1324HF, Arthrex™) suture anchor was placed in the arytenoid 10 mm
1423 cranial to the insertion of the CAD muscle as previously described.^{91,113} The suture was
1424 then threaded through the eyelet of the anchor from medial to lateral such that the two
1425 thread ends were in a relatively lateral position creating a single suture loop.

1426

1427 *6.3.3 Vacuum Chamber Model*

1428 A unidirectional vacuum system based on the *in vitro* models reported by Cheetham *et al.*
1429 2008 and others, was used for testing (Figure 1).^{74,86,94}

1430



1431

1432 Figure 1. Model set-up for airflow testing showing the plastic box with the test larynx
1433 inside connected to the vacuum cleaners. The camera is mounted with lights focused on the
1434 larynx to ensure a clear image with no shadows for easy evaluation.

1435

1436 To achieve a variable flow rate, two vacuum / blowers (Ryobi 2400W 230-240V 50 Hz),
1437 set on vacuum mode controlled using a variable autotransformer (Variac, Powertech SRV-
1438 5), attached to a ergospirometer (Quadflow Equine Spirometry, QF, RobacScience Pty
1439 Ltd) were connected via a 50mm PVC pipe to the testing chamber. The chamber was

1440 15x15x30cm with a 50mm hole at both ends of the chamber to allow for insertion of the
1441 50mm pipe attached to the vacuum system and a variable inlet valve at the other end. A
1442 hole was drilled into the dorsal surface of the 50mm PVC pipe and into the flow chamber
1443 cranial to the position of the larynx to insert the catheters of the differential pressure
1444 transducer (Digitron Differential Pressure Transducer). Each larynx was affixed to the
1445 PVC pipe using cable ties to ensure an airtight seal between the tracheal rings and the pipe.
1446 The epiglottis was secured to a piece of balsawood on the bottom of the flow chamber
1447 using an 18-gauge needle. A 20x20mm white cardboard square was affixed to the
1448 balsawood in the same plane as the *rima glottidis* as a reference and in frame of a digital
1449 camera (HC-V250 high definition digital camera, Panasonic, Osaka, Japan), which was
1450 mounted above the inlet valve and focused on the *rima glottidis*.

1451 Subsequently, the left arytenoid was maximally abducted using the Fiberwire equal to the
1452 right arytenoid and the flow and inlet valve altered to achieve a target flow rate of 55L/sec
1453 and a pre-laryngeal pressure (representative of pharyngeal pressure) of 12mmHg. This was
1454 achieved by adjusting the inlet valve and the voltage regulator to achieve a flow and
1455 pressure similar to previously reported *in vitro* and *in vivo* studies.^{74,86,94,116,118} The
1456 Fiberwire was then completely loosened to allow for testing to commence. Each larynx
1457 was tested under static airflow conditions for a single five second period to obtain data
1458 during sequential testing as outlined below. Airflow data (flow in L/s and translaryngeal
1459 differential pressure in mmHg) were recorded for the entire five seconds of testing and the
1460 middle three seconds averaged for analysis. Translaryngeal impedance was calculated by
1461 dividing the translaryngeal pressure differential by the flow to produce the TLI
1462 (mmHg/L/s).

1463

1464 *6.3.4 Left to Right Quotient Angle (LRQ) and Cross Sectional Area (CSA)*

1465 A still image was obtained after securing the construct at the desired position and before
1466 (“before”) the airflow test was initiated. Subsequently, a still image was obtained at 2.5
1467 seconds into (“during”) each five second test period. These images were used to calculate
1468 the resultant LRQ and CSA for both before and during each test. The change in LRQ
1469 (Δ LRQ) and CSA (Δ CSA) was calculated by subtracting the before and during values as a
1470 means to detect any dynamic airway collapse of the *rima glottidis* caused by airflow
1471 testing. The LRQ and CSA was measured and calculated as previously described from
1472 each photograph by one observer using a soft-ware package (Image J, Bethesda,
1473 USA).^{51,110} In short, for LRQ a line was drawn from the ventral to dorsal aspect of the *rima*
1474 *glottidis* and extended by one third to give a point that was used to measure the left (L°)
1475 and right (R°) arytenoid angles. The LRQ was then calculated by dividing L° from R° .
1476 Similarly, using Image J the 20x20 mm white square was used to set the scale of the
1477 program to each photograph and subsequently, the CSA of the *rima glottidis* was
1478 determined in mm^2 .

1479

1480 *6.3.5 Phase 1 testing – suture shortening*

1481 For Phase 1 testing, the ends of the suture at the middle of the lateral aspect of the cricoid
1482 cartilage were attached to the arms of a Vernier Calliper to allow for progressive controlled
1483 construct shortening at 3mm increments by opening the calliper arms as previously
1484 reported.¹¹⁹ Airflow testing, as outlined previously, was completed sequentially for each of
1485 the following steps; 0 mm (suture loop tight and secured but no change in arytenoid
1486 position from resting) and then successive 3 mm shortening to a maximum of 30 mm of
1487 shortening (a total of 11 steps per larynx).

1488

1489 *6.3.6 Phase 2 testing – DLPS activation*

1490 Immediately following Phase 1 testing of each larynx, the suture was tied routinely with a
1491 surgeon’s knot and 4 single throws to fix the left arytenoid at an approximate “before”
1492 LRQ of 0.5 (i.e. left arytenoid at approximately half of the right sided maximal abduction).
1493 This starting LRQ was selected based on previous *in vitro* analysis that demonstrated that
1494 maximal activation of the DLPS was able to cause an increase in LRQ from 0.7 to 0.97 (an
1495 effective range of 0.27).¹¹⁹ As a result, if the target LRQ at maximal abduction to
1496 significantly reduce TLI was to be approximately 0.75 (approximately a CSA of 88%) then
1497 the starting LRQ was estimated to be approximately 0.48 (i.e. $0.75-0.27=0.48$). To allow
1498 for a margin of error given that this testing involved negative airway pressures and the
1499 previous *in vitro* study that generated the LRQ effective range of 0.27 was in resting
1500 larynges, we selected a starting LRQ for testing of 0.5.

1501 Subsequently, the prototype was completed by inserting the DLPS into position between
1502 the completed suture loop. An inactivated baseline position (approximate LRQ of 0.5) and
1503 then two levels of activation were achieved by variably injecting saline into the catheter
1504 port. The level of activation was selected based on previous mechanical testing results;
1505 inactivated (0psi), moderate activation (25psi) and maximal activation (50psi).¹¹⁵ As
1506 previously reported, the injection pressure was measured using a pressure syringe (Blue
1507 Diamond™ Merit Medical).¹¹⁵ If a pressure of 50psi was not achieved the maximal
1508 pressure was recorded and the reason for failure to achieve 50psi also recorded.

1509

1510 *6.3.7 Statistical Analysis*

1511 Data is reported as mean \pm standard error of the mean (SEM). Normality was assessed with
1512 a Shapiro-Wilk test. Comparison of normally distributed data (impedance before and after
1513 testing) was made using a paired *t*-test. Changes in variables of interest (TLI, Δ CSA,

1514 Δ LRQ) between baseline and at subsequent degrees of shortening and DLPS activation
1515 were compared using a repeated-measure analysis of variance (ANOVA). A Tukey *post-*
1516 *hoc* test was used when appropriate. Generalised estimating equations (GEE) or simple
1517 linear regressions were used to model the effect of shortening or DLPS activation on CSA
1518 and LRQ with (after) or without (before) flow. Significance was defined as $p < 0.05$.

1519

1520

1521 6.4 Results

1522 All testing was completed and data recorded without complication. The baseline flow and
1523 pre-laryngeal pressure at maximal bilateral arytenoid abduction (an LRQ of 1.0) prior to
1524 testing was 56.30 (± 0.1) L/sec and 11.90 (± 0.03) mmHg respectively.


1525

1526 6.4.1 Phase 1 testing

1527 Progressive construct shortening from 0mm (0.60 ± 0.11 mmHg/L/sec) to 6mm
1528 (0.30 ± 0.07 mmHg/L/sec) had a significant effect on reducing TLI ($p = 0.001$) (Figure 2).

1529 Further shortening to 9 mm (0.23 ± 0.05 mmHg/L/sec) or more caused additional smaller but
1530 non-significant reductions in TLI ($p > 0.05$).

1531




1532

1533 Figure 2. Change in TLI related to construct shortening in progressive 3 mm steps. Letters
 1534 denote statistical significance.

1535

1536 Similarly, the Δ LRQ was significant ($p < 0.001$) from 0mm (0.25 ± 0.03) to 6mm
 1537 (0.15 ± 0.02) but stopped being significant with further shortening ($p > 0.05$). The Δ CSA was
 1538 significant from 0mm ($721.98 \pm 57.89 \text{mm}^2$) to 15mm ($350.88 \pm 35.73 \text{mm}^2$) but stopped
 1539 being significant with further shortening ($p < 0.001$) (Figure 3). During testing vocal fold
 1540 collapse was note to occur in 3/10 larynges at maximal shortening. At 12mm of suture
 1541 shortening (equivalent to maximal DLPS activation) 6/10 larynges were noted to have
 1542 vocal fold collapse.

1543



1544
 1545 Figure 3. Representative images of rima glottis demonstrating Δ LRQ and Δ CSA between
 1546 “before” (left) and “during (right) airflow tests for larynx #10 at 0,15,30mm (top, middle
 1547 and bottom images respectively) of shortening. This represents a Δ LRQ and Δ CSA of 0.39
 1548 and 695.56mm^2 , 0.09 and 382.64mm^2 , 0 and 137.67mm^2 , for 0,15 and 30mm of shortening
 1549 respectively.


1550

1551 *6.4.2 Phase 2 testing*

1552 Activation of the DLPS prototype caused a significant reduction in TLI from 0 psi
 1553 ($0.43\pm 0.08\text{mmHg/L/sec}$) to 25 psi ($0.16\pm 0.04\text{mmHg/L/s}$)($p<0.001$) and a smaller non-

1554 significant additional reduction in TLI ($0.13 \pm 0.03 \text{ mmHg/L/sec}$) ($p > 0.05$) with maximal
1555 activation (Figure 4).

1556



1557


1558 Figure 4. Change in TLI with DLPS activation. Letters denote differences in TLI of
1559 statistical significance ($p < 0.05$).

1560

1561 A maximal activation of 31.3 ± 0.96 psi was achieved during testing. Additional activation
1562 beyond this psi caused balloon prolapse from the DLPS and did not result in further change
1563 in arytenoid abduction. Using the results from Phase 1 of the study, maximum activation
1564 of the DLPS was found to have an effect on TLI reduction equivalent to approximately 12
1565 mm of suture shortening.

1566 There was significant reduction in Δ LRQ (dynamic arytenoid collapse) (Figure 6) at both
1567 levels of activation of the DLPS (25psi and max psi) compared to baseline (0 psi) (both
1568 $p < 0.05$) (Figure 5).

1569




1570

1571 Figure 5. LRQ both before and during airflow testing with 3 levels of DLPS activation
1572 during airflow testing. Δ LRQ is the difference between the 2 at each level. Letters denote
1573 differences of statistical significance ($p < 0.05$).

1574

1575 The Δ CSA was reduced by activation of the DLPS at both levels of activation compared to
1576 baseline but not significantly so (0, 25 and max psi, all $p > 0.05$) (Figure 6). During testing
1577 vocal fold collapse was noted to occur in 5/10 larynges at maximal psi activation.

1578



1579

1580 Figure 6. CSA both before and during airflow testing with 3 levels of DLPS activation
 1581 during airflow testing. Δ CSA is the difference between the 2 at each level. Letters denote
 1582 differences of statistical significance ($p < 0.05$).

1583

1584 6.5 Discussion

1585 The aim of the study presented here was to evaluate the DLPS prototype's ability to affect
 1586 and maintain a reduction in TLI using a static airflow model. This study followed on from
 1587 previous *in vitro* evaluations using a mechanical testing system that had found the
 1588 prototype able to produce construct shortening of 7.11 mm whilst under a static 10 N load.
 1589 Additionally, a separate study had found the prototype able to cause increases in LRQ in
 1590 cadaveric larynges equivalent to 18.7 mm of construct shortening.¹¹⁹ Based on the results
 1591 of the study reported here we supported our first hypothesis by finding the DLPS was able
 1592 to achieve a reduction in TLI equivalent to approximately 12 mm of construct shortening.
 1593 We partly supported the second hypothesis in that the DLPS prevented dynamic collapse
 1594 as determined by 25 psi and maximal activation preventing Δ LRQ but were not able to
 1595 prevent Δ CSA during testing.

1596 *6.5.1 Translaryngeal impedance*

1597 The results from phase 1 of the study found that after 6 mm of construct shortening
1598 (tightening the suture) there was no additional reduction in the TLI. This is interesting as it
1599 indicates that relatively little shortening of the laryngoplasty suture construct can result in
1600 effective reductions in TLI that may be important for clinical success. Previous
1601 computational fluid mechanic modelling to measure the effects of different degrees of
1602 arytenoid abduction on upper airway characteristics found that a left arytenoid cartilage
1603 position resulting in 88% and 75% larynx cross-sectional areas resulted in 4.11 and 5.65%
1604 reductions in peak airflow.²¹ Back calculating from our results, 88% and 75% would be
1605 equal 15-18mm (LRQ 0.7-0.75) and 6mm (LRQ 0.54) respectively (data not shown). Our
1606 results suggest that at 55L/sec flow, the minimum arytenoid abduction required to
1607 ameliorate negative effects on TLI would be an LRQ of 0.54 or a CSA of 75%. These
1608 finding may partially explain the results reported by Barakzai *et al* in 2009 that found post-
1609 operative performance after LP was not correlated with the degree of arytenoid abduction
1610 and suggested that horses with a post-operative grade 3 abduction (moderate degree of
1611 arytenoid abduction, approximately LRQ of 0.5-0.6) can race successfully.¹¹¹ However, the
1612 flow rates expected in maximally exercising Thoroughbreds have been reported to range
1613 from 65-100L/s and it is likely that the degree of shortening required to ameliorate any
1614 negative effects on TLI at these higher flow rates may be higher than the 6 mm reported in
1615 our study.^{8,9,21,38,120,121} The flow rates used in our study are similar to those used in
1616 previous *in vitro* studies.^{74,94,116} Unfortunately, it was not possible to evaluate the effect of
1617 higher flow rates due to system limitations with regards to effectively measuring flow.
1618 Further *in vitro* studies evaluating the effects on TLI at higher flow rates will be required
1619 to determine what effect this will have on the required degree of arytenoid abduction to
1620 ameliorate negative effects on TLI.

1621 The results of phase 2 of the study demonstrate that the DLPS was able to reduce TLI
1622 when activated. The reduction in TLI was significant from 0 psi to 25 psi but maximal psi
1623 caused a smaller (non-significant) additional reduction. This may be due to the maximal
1624 psi being only 31.3 psi, as the target of 50 psi was not achieved due to the balloon segment
1625 of the DLPS prolapsing. This indicates that the target psi of 50 psi was too high when used
1626 *in vitro* likely because there is minimal resistance to inflation of the balloon in cadaveric
1627 larynges. *In vivo* the target activation psi will have to be determined but these *in vitro*
1628 findings suggest the maximum benefit of the DLPS prototype will be above 25 psi but
1629 below 50 psi, likely around 30 – 35 psi. Calculations (data not shown) using the data from
1630 this study revealed that no activation (0 psi) represented an LRQ of 0.49 and CSA of 66%,
1631 25 psi activation represented and LRQ of 0.71 and CSA of 0.77% and maximal activation
1632 represented an LRQ of 0.76 and CSA of 0.82%. When the performance of the DLPS is
1633 compared to the phase one results of this study and the computational modelling of Rakesh
1634 *et al* 2008, the DLPS device was able to achieve increases in LRQ / CSA and resultant
1635 reductions in TLI that should be useful *in vivo*.

1636

1637 *6.5.2 Dynamic laryngeal collapse*

1638 To evaluate our second hypothesis, we used the Δ LRQ and Δ CSA as a means of evaluating
1639 for any dynamic collapse produced by initiation of the airflow used in this vacuum system.
1640 Interestingly, the DLPS was able to prevent significant dynamic arytenoid collapse as
1641 measured by the Δ LRQ at both 25 psi and maximal psi but not when considered using
1642 Δ CSA. Review of the dynamic video recordings demonstrated this difference was mostly
1643 due to vocal fold collapse that influences Δ CSA measurements but not Δ LRQ. In phase 1
1644 of the study at maximal shortening 3/10 larynges had vocal fold collapse compared to in
1645 phase 2 at maximal DLPS activation 5/10 larynges had vocal fold collapse. As a result of

1646 this difference, we partly supported our second hypothesis depending on which measure of
1647 dynamic collapse was selected. A similar finding occurred in the phase 1 of this study with
1648 the Δ CSA being significant for 15 mm and the Δ LRQ for only 6 mm of shortening.
1649 Review of the images similarly found this was due to vocal fold collapse. Overall, these
1650 results support the clinical practise of performing a vocal cordectomy or ventriculectomy
1651 in conjunction with a LP to prevent dynamic collapse of the rima glottis due to vocal fold
1652 collapse. Similarly, clinical use of the DLPS will also benefit from a concurrent vocal
1653 cordectomy or ventriculectomy.

1654

1655 *6.5.3 Model limitations*

1656 A major limitation of this model is that the airflow target of 55 L/s used, whilst in
1657 accordance with similar previous *in vitro* research, represents an airway pressure of horses
1658 exercising at approximately 100% VO₂max.¹¹⁸ However, airflows of up to 100 L/s have
1659 been recorded in maximally exercising horses.³⁸ Testing using these higher flow rates
1660 would be useful for further *in vitro* evaluations with regards to Thoroughbred racehorses.
1661 However, due to system limitations of only being able to measure a maximum flow of
1662 60L/s and to allow for comparisons to previous research it was elected to select a target
1663 flow rate of 55 L/s.

1664 Further limitations of the model are related to the use of cadaveric larynges, which is
1665 inherent to *in vitro* testing. Specifically, there is no muscular function in cadaveric larynges
1666 that may potentially have an effect on arytenoid abduction and TLI *in vivo*. The possible
1667 effect of drying of the larynges during sequential testing influencing the results was
1668 considered prior to testing. While there is no specific effect of drying known, each test was
1669 limited to a 5 second period in an effort to ameliorate any effect this may have had. During
1670 this research, each larynx underwent 14 sequential tests (11 shortening and 3 DLPS levels),

1671 which was equal to a total of 70 seconds of active airflow during which no overt evidence
1672 of drying was noted. This period of airflow was similar to the 60 seconds used by
1673 Cheetham *et al.* 2008.⁸⁶ Finally, during our study the CAD muscle was transacted
1674 immediately caudal to its insertion on the muscular process. This was performed in an
1675 effort to minimise any potential effect the cadaveric CAD muscle may have on arytenoid
1676 position during the testing and ensure a free range of movement of the cricoarytenoideus
1677 joint. Clinically, surgeons may choose to transect the CAD muscle to improve access to the
1678 muscular process or to allow access to the cricoarytenoideus joint to facilitate fusion
1679 procedures.⁷⁴ For this experiment it was considered that transecting the CAD would
1680 minimise any potential effect the cadaveric CAD muscle may have between larynges,
1681 simulate complete laryngeal paralysis and as a result allow for the most accurate
1682 comparisons to be performed.

1683

1684 In conclusion, the prototype DLPS was able to cause reductions in TLI using a static
1685 airflow model. This reduction in TLI was approximately equal to 12 mm of suture
1686 shortening (tightening). The DLPS was able to prevent dynamic arytenoid collapse as
1687 measured by lack of change in the LRQ but did not prevent dynamic vocal fold collapse,
1688 resulting in an overall decrease in CSA during dynamic testing. Overall, the DLPS
1689 prototype evaluated using this *in vitro* airflow system was shown to be able to achieve and
1690 maintain arytenoid abduction that was beneficial to airflow. Based on these results further
1691 evaluation *in vivo* is supported.

1692

1693

1694

PART IV: *IN VIVO* PROOF OF CONCEPT STUDY

1695

1703 **Co-Author Contributions**

1704 By signing the Statement of Authorship, each author certifies that:

- 1705 i. the candidate's stated contribution to the publication is accurate (as detailed
 1706 above);
- 1707 ii. permission is granted for the candidate to include the publication in the thesis; and
- 1708 iii. the sum of all co-author contributions is equal to 100% less the candidate's stated
 1709 contribution.

Name of Co-Author	Andrew W. Van Eps		
Contribution to the Paper	Designed experiments (10%) Critically reviewed paper (50%)		
Signature		Date	20/6/17

1710

Name of Co-Author	Samantha H. Franklin		
Contribution to the Paper	Designed experiments (10%) Critically reviewed paper (50%)		
Signature		Date	20/06/17

1711

1712 7.1 Abstract

1713 **Objectives-** Evaluation of a novel dynamic laryngoplasty system (DLPS) in horses – a
1714 feasibility study.

1715 **Study Design-** *In vivo* experimental.

1716 **Study units-** Adult horses (n=3).

1717 **Methods-** Three healthy Standardbred horses had a standing surgical procedure to induce
1718 complete laryngeal hemiplegia (transection of cricoarytenoideus dorsalis (CAD) tendon of
1719 insertion), which was subsequently treated using the DLPS. Activation of the DLPS was
1720 achieved using an injection port exiting through a skin stab (n=2) or using a subcutaneous
1721 injection port (n=1). Endoscopic examinations of the upper respiratory tract were
1722 performed pre-, intra- and at 7 days post-operatively. Left to right quotient (LRQ) ratios
1723 calculated during inactivated and activated states were obtained from still images of the
1724 rima glottis acquired at 7 days post-operatively. After these images were acquired the
1725 device was intentionally overinflated to evaluate for device failure. Post-mortem
1726 examinations were performed on day 7 to evaluate placement of the DLPS and to evaluate
1727 any complications or failures.

1728 **Results-** No complications occurred in the 7-day post-operative period and the DLPS was
1729 effectively positioned in all 3 horses during a standing procedure. The LRQ at day 7 post-
1730 operatively could be varied from a resting position of 0.73 (+/-0.07) to a maximum of 1.01
1731 (+/-0.06). At post-mortem, all DLPS components were functional with 2 not between the
1732 suture loop and the 3rd modified DLPS in the correct location.

1733 **Conclusions-** Using the DLPS it was possible to alter the degree of left arytenoid
1734 abduction post-operatively in 3 adult horses with experimentally induced laryngeal
1735 hemiplegia. Minor modification of the device to restrain the suture loop within the device
1736 prevented failure caused by intentional over inflation.

1737 **Clinical Relevance-** The DLPS may provide a useful alternative to traditional LP but
1738 requires further long term investigation.

1739 7.2 Introduction

1740 The dynamic laryngoplasty system (DLPS) has been developed with the overarching goal
1741 of being able to alter the degree of arytenoid abduction post-operatively in horses. With
1742 this goal in mind, the developed prototype has been evaluated *in vitro* in 3 steps. The first
1743 step was mechanical testing of the device demonstrating the device could cause functional
1744 shortening of a suture loop whilst under a static load likely to be seen *in vivo*.¹¹⁵ The
1745 second step demonstrated the device was able to cause increased arytenoid abduction when
1746 activated.¹¹⁹ The final third step using a static airflow model demonstrated the device was
1747 able to reduce translaryngeal impedance when activated.¹¹⁹ Based on these *in vitro* findings
1748 a proof of concept *in vivo* study was proposed to evaluate DLPS deliverability and
1749 performance for the short term post-operative period.

1750 The aims of this study were to 1) evaluate the surgical delivery of a DLPS in standing
1751 horses, 2) determine the ability of the device to alter arytenoid abduction via an injection
1752 port at 7 days post-operatively and 3) evaluate the devices' location at post-mortem
1753 examination for any errors in delivery or other types of failure.

1754 We hypothesised that the DLPS 1) would allow for effective controllable alteration in
1755 arytenoid abduction at 7 days post-operatively, and 2) would not cause significant
1756 complications associated with its use. We elected to perform the surgery in a standing
1757 position, as previously reported, to allow for intra-operative assessment of arytenoid
1758 positioning during DLPS placement.⁷²

1759

1760 7.3 Materials and Methods

1761 Three adult Standardbred horses aged between 4-10 years old were enrolled in this study,
1762 which had institutional animal ethics approval (SVS/220/16). All horses' larynges palpated


1763 normally and an endoscopic examination at rest revealed normal laryngeal anatomy and
1764 function (Havemeyer grade 1 or 2) with no evidence of gross tracheal contamination.

1765

1766 *7.3.1 Surgical procedure*

1767 All horses were restrained in stocks, sedated (using detomidine hydrochloride 0.01mg/kg
1768 IV and butorphanol tartrate 0.01mg/kg IV), and prepared for standing surgery. A video
1769 endoscope was placed via the right nostril and attached to the rope halter in a position to
1770 maintain the larynx in view throughout the procedure. Subsequently, an approach to the
1771 left side of the larynx was performed as previously reported for a standing laryngoplasty
1772 technique.⁷² In brief, a 10cm long subcutaneous line of local anaesthetic was injected
1773 immediately ventral to the left linguofacial vein and an incision made along this line. A
1774 combination of sharp and blunt dissection ventral to the vein was performed to allow
1775 access to the left dorsolateral aspect of the larynx. At this point the tendon of insertion of
1776 the left cricoarytenoideus (CAD) muscle was isolated and transected to induce complete
1777 left laryngeal dysfunction, which was confirmed using the video endoscope. The DLPS
1778 was then placed as follows: Using a trocar point half circle needle, #2 Fiberwire (Arthrex)
1779 suture was passed through the cricoid cartilage approximately 1.5cm lateral to the midline
1780 and 1.5cm from the caudal edge. For the arytenoid attachment a FASTak[®] II (AR-1324HF,
1781 Arthrex) suture anchor was placed in the muscular process of the arytenoid cartilage,
1782 10mm cranial to the insertion of the CAD muscle as described previously (Figure 1A).¹¹³
1783 The balloon element of the DLPS was then placed in position between the resultant suture
1784 loop (Figure 1B). At surgery, the left arytenoid was placed at an estimated left to right
1785 quotient (LRQ) angle of 0.7 when the DLPS was in an inactivated state. In the first two
1786 horses the attached catheter was exited through a stab skin incision at the caudal aspect of
1787 the incision prior to routine closure in layers. For the final horse the DLPS was modified to

1788 prevent suture prolapse (a PEEK pillar perpendicular to the suture direction connecting the
1789 PEEK discs) and the catheter was tunnelled subcutaneously (Figure 1C) and connected to
1790 an injection port (Vital-Port® titanium vascular access system, IP-S7110, Cook Medical)
1791 (Figures 1D and 1E) that was placed in a subcutaneous pocket via a 3cm skin incision on
1792 the neck (Figure 1F). The catheters and the subcutaneous injection port were used to
1793 activate the DLPS by injection of saline into the exposed port or via a needle inserted
1794 transcutaneously.
1795



1796
1797 Figure 1. Intra-operative images of horse 3 demonstrating, A) arytenoid anchor placement,
1798 B) DLPS (with added pillar) being placed, C) catheter tunnelled subcutaneously, D)
1799 injection port being tested, E) subcutaneous injection port being placed and F) final post-
1800 operative appearance.
1801

1802 *7.3.2 Post-operative care / examinations*

1803 All horses received procaine penicillin (22,000IU/kg) intramuscularly twice a day,
1804 gentamicin (8.8mg/kg) intravenously once a day and phenylbutazone (2.2mg/kg) orally
1805 once a day for 5 days post-operatively. Horses were fed from the ground in a hospital box
1806 for the duration of the study. At the completion of the study (7 days post-operatively) the
1807 horses were restrained in stocks and an endoscopic examination of the larynx and trachea
1808 performed via the right nostril. Any gross evidence of tracheal contamination was noted.
1809 Whilst observing the larynx endoscopically, the DLPS was activated by injection of saline
1810 (range 3-4ml) to assess the range of arytenoid abduction attainable and during maximal
1811 right arytenoid abduction. Once this was performed several times the DLPS was
1812 intentionally overinflated with 6 mls of saline. For the first two horses this activation was
1813 performed via the injection port exiting the surgical incision or in the final horse via the
1814 subcutaneous injection port using a needle inserted transcutaneously. Digital recordings
1815 were made of the endoscopic examinations at 7-days post-operatively and still images
1816 obtained pre-and post-inflation at points of maximal right arytenoid abduction.
1817 Subsequently, all horses were euthanized and the surgical site dissected to evaluate for any
1818 errors in device placement (i.e. if not located between the suture loop) or other types of
1819 failure (e.g. anchor movement, balloon rupture, prolapse or other construct failure).

1820

1821 *7.3.3 Left to Right Quotient angle ratio (LRQ)*

1822 Arytenoid LRQ was measured and calculated as previously described from each still image
1823 by an experienced observer (B.A.) using Image J.^{51,110} In short, using a digital image,
1824 acquired during maximal stimulated right arytenoid abduction, a line was drawn from the
1825 ventral to the dorsal aspect of the *rima glottidis* and then extended by one third to give a

1826 point that was used to measure the left (L°) and right (R°) arytenoid angles. The LRQ was
1827 then calculated from dividing L° from R° .

1828

1829 All data reported as mean +/- SD throughout unless otherwise stated.

1830


1831 7.4 Results

1832 All surgical procedures were completed without complications, were of less than 45
1833 minutes' duration and did not require additional doses of sedation. The DLPS device was
1834 readily positioned without complication.

1835 Post-operatively all horses were clinically normal with no evidence of excessive pain or
1836 swelling of the surgical site and maintained a normal appetite for the duration of the study.

1837 During the post-operative period, no coughing or nasal discharge noted. Routine wound
1838 management was required for the 2 cases with catheters exiting the skin, with mild serous
1839 drainage being cleaned daily. The subcutaneous portal was visible and easily palpated.

1840 Injection into the portal was easily performed with routine restraint. The LRQ at day 7
1841 post-operatively could be varied from a resting position of 0.73 (+/-0.07) to a maximum of
1842 1.01 (+/-0.06) (Figure 2 and 3).



1843

1844 Figure 2. LRQ (mean +/- SD) at 7 days post-operatively pre-and post-inflation of the

1845 DLPS.



1846

1847 Figure 3. Endoscopic images of the three horses (top to bottom) at day 7 post-operatively

1848 pre (left) and post (right) inflation of the DLPS in each horse respectively.

1849

1850 Intentional over inflation of the balloon using 6 mls of saline caused a sudden loss of
1851 abduction in the first two horses. This loss of abduction did not occur in the third horse and
1852 in this horse additional injections of saline caused no apparent effect on the observed
1853 maximal arytenoid abduction. When the saline was removed in the third horse after over
1854 inflation, the arytenoid returned to the resting position. Endoscopic examinations of the
1855 trachea revealed no gross evidence of food aspiration in any case.

1856 At post-mortem, for the first two horses, the device was displaced from the suture loop and
1857 sitting immediately adjacent and dorsal to the suture loop. The balloons were intact and the
1858 DLPS unit functional but out of position. For the third horse the DLPS was in place and
1859 activation of the device caused changes in arytenoid abduction as expected. Overall, the
1860 remainder of the construct (suture loop and anchor) were in place without evidence of
1861 failure in all three horses. There was a smooth lined tissue space at the surgical site with a
1862 small amount of serous fluid.

1863

1864 7.5 Discussion

1865 We aimed to evaluate the feasibility of delivering a prototype DLPS in standing horses that
1866 was able to selectively alter arytenoid abduction at 7 days post-operatively. Based on the
1867 results from this limited number of horses we achieved “proof of concept” that post-
1868 operative selective alteration of arytenoid abduction was feasible using a prototype DLPS.
1869 Specifically, we supported our first hypotheses in that the DLPS allowed for effective
1870 controllable alteration in arytenoid abduction at 7 days post-operatively. Regarding our
1871 second hypothesis, no post-operative complications were identified in any of the three
1872 horses over the 7 days of the study. However, over inflation of the device in the first two
1873 horses led to displacement of the suture, leading to a failure to abduct the arytenoid
1874 cartilage on subsequent attempts. A post-mortem examination found the DLPS were not in

1875 the correct position between the suture loop (displaced), which prompted a minor device
1876 modification for the third horse to prevent this displacement occurring. As a result of this
1877 modification and despite intentional over-inflation the 3rd device was in correct position
1878 and able to cause changes in arytenoid abduction. The balloon and PEEK components
1879 remained intact in all three cases.

1880

1881 This was a pilot study and clearly has the limitations of only a small number of horses and
1882 only a short survival period. This study suggests that the device is well tolerated and
1883 allows for variable adjustment of arytenoid positioning in the short term. Longer term
1884 evaluation of the device should investigate the effects of potential peri-prosthesis fibrosis
1885 or long term failure due to repetitive loading.

1886

1887 From a mechanical point of view, recent *in vitro* evaluation using limited cyclical and
1888 ramp to failure testing suggests that the balloon element of the device should be able to
1889 withstand at least preliminary *in vivo* loading.¹¹⁵ The remaining element of the DLPS is
1890 made from polyetheretherketone (PEEK) which is commonly used in medical devices as it
1891 is safe, easily manufactured and impervious to moisture and degradation.¹²² Finally, the
1892 catheter and injection port (used in horse three) is a subcutaneous portal system already
1893 used routinely in human medicine.¹²³ As a result, it is expected that these components will
1894 be very robust. The balloon component, whilst used in medical settings in an indwelling
1895 location, is the relative point of weakness in the DLPS prototype due to the cyclical
1896 functionality required. This component will warrant evaluation regarding longer term *in*
1897 *vivo* performance as it has not been used previously in a similar setting that we are aware
1898 of. At post-mortem, the DLPS in the first two horses had been displaced from between the
1899 suture loops by intentional over inflation of the balloon. This was done in an effort to

1900 determine if the balloon would rupture or how the device would fail. For the third horse the
1901 PEEK element of the DLPS had a pillar of PEEK added at both peripheries of the device at
1902 180° to each other and perpendicular to the suture loop, to prevent the suture from
1903 displacing from within the confines of the device. At post-mortem, this device was still in
1904 location and functioning. This minor modification to prevent accidental over inflation
1905 should be used in all future similar devices.

1906 How the DLPS will perform in an exercising pressurised larynx is also unknown at this
1907 time. Previous *in vitro* testing found the construct to be very stiff and 9 out of 10 constructs
1908 did not fail during ramp loading to 100N.¹¹⁵ Furthermore, an *in vitro* evaluation of the
1909 DLPS using a static airflow model showed the DLPS could achieve an increase in and
1910 maintain arytenoid abduction that resulted in a significant reduction in translaryngeal
1911 impedance during airflows of 55L/second.¹²⁴ As a result of the previous *in vitro*
1912 evaluations and this *in vivo* proof of concept pilot the DLPS warrants further longer term
1913 evaluation likely using an exercising model.

1914 Delivery of the DLPS *in vivo* during a standing procedure was readily achieved in this pilot
1915 study. Surgical familiarity with the DLPS and technique is essential prior to attempting
1916 effective delivery and will be directly related to surgical outcome. Standing surgical
1917 delivery was considered to be desirable to allow for the most accurate selection of the
1918 desired degree of arytenoid abduction during normal respiration. However, the DLPS
1919 could be used under general anaesthesia if desired and the authors have performed the
1920 procedure using cadaveric horses in lateral position as for a more traditional laryngoplasty
1921 performed under general anaesthesia.

1922

1923 There are a number of potential uses for the device including correction of disappointing
1924 post-operative abduction, or to correct more gradual post-operative abduction loss.

1925 Secondly, the device might be used to selectively increase the degree of arytenoid
1926 abduction during periods of exercise and improve the athletic performance of the horse as
1927 a result. Finally, the device might also be used for research applications related to the
1928 effects of differing degrees of arytenoid abduction on airflow and lower airway
1929 contamination, using each horse as its own control.

1930 The clinical significance of being able to alter the degree of arytenoid abduction post-
1931 operatively with regards to the incidence of longer-term complications and general
1932 performance are unknown. However, the results of this research achieved our aim of
1933 delivering the DLPS in sedated standing horses and allowed for effective alteration in the
1934 degree of arytenoid abduction at 7 days post-operatively. Based on the results of this study
1935 further longer term evaluation of the DLPS and exercise studies are warranted.

1936

1938 **Chapter 8: General Discussion**

1939 At the outset of this thesis we set out to develop a laryngoplasty technique that was
1940 fundamentally different to the traditional laryngoplasty in that it could be altered post-
1941 operatively. We theorised this may be useful to equine surgeons to allow for increased
1942 arytenoid abduction as a minimum and additionally might allow for a dynamic or variable
1943 laryngoplasty construct that could be used to “select” the optimal degree of arytenoid
1944 abduction for an individual horse.

1945 We were successful in developing a DLPS that was able to produce and maintain a
1946 variable degree of arytenoid abduction in the face of representative airflows *in vitro*.
1947 Furthermore, we validated the prototype during a proof of concept *in vivo* study and found
1948 the DLPS allowed for controlled variation of the arytenoid position at 7 days post-
1949 operatively. This is the first reported laryngoplasty device that can readily and effectively
1950 cause alteration in the degree of arytenoid abduction post-operatively. This prototype or
1951 one of similar concept might be clinically useful to improve the success rate for horses
1952 treated for dynamic laryngeal collapse caused by RLN. Numerous different prototypes
1953 were conceived and subsequently discarded due to a variety of reasons prior to
1954 development of the final prototype DLPS that was used for *in vitro* and *in vivo* testing.
1955 During the final stages of the *in vivo* testing, a small modification of the device was made
1956 to prevent accidental over inflation. It is possible that with further *in vivo* study, such as
1957 using an exercising model, further modifications may need to be made in an effort to
1958 improve the functionality of the device.

1959 The portion of the device that is the weak point is the balloon component. There are a
1960 variety of materials that the balloon can be made from and if this element of the device is a
1961 problem in future research than it will have to be revised. That being said, the remainder of
1962 the prototype is extremely robust and unlikely to fail *in vivo*. As a result of the robustness

1963 of the device when inactivated (no balloon element functioning), the inactivated position
1964 selected at surgery should be at the lowest end of what is considered to be the minimal
1965 degree of arytenoid abduction. Based on the above research this would represent a target of
1966 slightly over a resting LRQ of 0.5 or a CSA of 0.75%, which equates to approximately
1967 6mm of effective construct shortening. This degree of arytenoid abduction ameliorated the
1968 negative effects on TLI using an *in vitro* static airflow model with flow rates of 55L/min,
1969 similar to those that would occur at approximately 100% VO_{2max} .¹¹⁸ Horses maximally
1970 exercising will generate flow rates significantly higher than this (reported up to 100L/sec)
1971 and they will likely benefit from a higher degree of arytenoid abduction that will be
1972 possible using the DLPS post-operatively.^{8,120,121} This should result in maximisation of
1973 airway function by specifically allowing it to be tailored to an individual horse.

1974 The effectiveness of the developed DLPS to return airflow mechanics and exercise
1975 capacity to normal whilst reducing complications such as tracheal contamination is
1976 currently unknown. Future work will include evaluating the DLPS using an exercising
1977 model similar to the one used by Radcliffe et al. (2006) that compared horses in 3 phases.
1978 These phases were; normal laryngeal function, induced laryngeal hemiplegia and after
1979 treatment with laryngoplasty or arytenoidectomy. We intend to evaluate the prototype
1980 using horses completing an exercise test on a high-speed treadmill at or as close as possible
1981 to racing speeds and conditions. The horses will undergo testing at; 1) normal laryngeal
1982 function, 2) induced laryngeal dysfunction and then using 2 arms, after treatment using
1983 either a traditional laryngoplasty or a DLPS. Similar to the Radcliffe et al. (2006) study the
1984 rate of complications and ability to return horses with laryngeal collapse to normal will be
1985 evaluated. After this exercising evaluation and over a longer term, the horses will be
1986 monitored intermittently to evaluate for any effect on functionality caused by potential
1987 fibrosis.

1988 In conclusion, we developed a prototype DLPS and evaluated it thoroughly *in vitro* prior
1989 to demonstrating the proof of concept of the device *in vivo*. We demonstrated the effective
1990 surgical deliverability of the DLPS in horses using a standing sedated approach. Using the
1991 DLPS device the degree of arytenoid abduction could be effectively altered post-
1992 operatively which may be useful to equine surgeons in the future.

1993

REFERENCES

- 1994 1. Hawkins JF, Tulleners EP, Ross MW, et al. Laryngoplasty with or without
1995 ventriculectomy for treatment of left laryngeal hemiplegia in 230 racehorses. *Vet Surg*
1996 1997;26:484–491.
- 1997 2. Russell AP, Slone DE. Performance analysis after prosthetic laryngoplasty and bilateral
1998 ventriculectomy for laryngeal hemiplegia in horses: 70 cases (1986-1991). *J Am Vet Med*
1999 *Assoc* 1994;204:1235–1241.
- 2000 3. Abeele K, van den Steenhaut M, Martens A, et al. Results of laryngoplasty combined
2001 with ventriculectomy in equine laryngeal hemiplegia: a review of 105 cases. *Vlaams Dier*
2002 *T* 1997;66(6):298–302.
- 2003 4. Kraus BM, Parente EJ, Tulleners EP. Laryngoplasty with ventriculectomy or
2004 ventriculocordectomy in 104 draft horses (1992-2000). *Vet Surg* 2003;32:530–538.
- 2005 5. Fulton IC, Anderson BH, Stick JA, Robertson JT. Larynx. In: Auer JA, Stick JA. *Equine*
2006 *Surgery* 4th ed. W B Saunders Company; 2012;592-623.
- 2007 6. Art T, Anderson L, Woakes AJ, et al. Mechanics of breathing during strenuous exercise
2008 in Thoroughbred horses. *Respir Physiol* 1990;82:279–294.
- 2009 7. Lafortuna CL, Saibene F, Albertini M, et al. The regulation of respiratory resistance in
2010 exercising horses. *Eur J Appl Physiol* 2003;90:396–404.
- 2011 8. Art T, Lekeux P. Exercise-induced physiological adjustments to stressful conditions in
2012 sports horses. *Live Prod Sci* 2005;92:101–111.
- 2013 9. Rakesh V, Ducharme NG, Datta AK, et al. Development of equine upper airway fluid
2014 mechanics model for Thoroughbred racehorses. *Equine Vet J* 2008;40:272–279.
- 2015 10. Radcliffe CH, Woodie JB, Hackett RP, et al. A Comparison of Laryngoplasty and
2016 Modified Partial Arytenoidectomy as Treatments for Laryngeal Hemiplegia in Exercising
2017 Horses. *Vet Surg* 2006;35:643–652.
- 2018 11. Erickson BK, Seaman J, Kubo K, et al. Mechanism of reduction in alveolar-arterial
2019 PO₂ difference by helium breathing in the exercising horse. *J Appl Physiol* 1994;76:2794–
2020 2801.
- 2021 12. Rakesh V, Datta AK, Ducharme NG, et al. Simulation of turbulent airflow using a CT
2022 based upper airway model of a racehorse. *J Biomech Eng* 2008;130:031011.
- 2023 13. Hahn I, Scherer PW, Mozell MM. Velocity profiles measured for airflow through a
2024 large-scale model of the human nasal cavity. *J Appl Physiol* 1993;75:2273–2287.
- 2025 14. Sisson S, Grossman J. *The anatomy of the domestic animals*. 1975.
- 2026 15. Cole CR. Changes in the equine larynx associated with laryngeal hemiplegia. *Am J Vet*
2027 *Res* 1946;7:69–77.
- 2028 16. Robinson NE. Consensus statements on equine recurrent laryngeal neuropathy:

- 2029 conclusions of the Havemeyer Workshop. *Equine Vet Educ* 2004;16:333–336.
- 2030 17. Cramp P, Barakzai SZ. Surgical management of recurrent laryngeal neuropathy.
2031 *Equine Vet Educ* 2011;24:307–321.
- 2032 18. Baker GJ. Laryngeal Hemiplegia in the Horse. *Comp com Educ* 1983;5:S61–S67.
- 2033 19. Derksen FJ, Stick JA, Scott EA, et al. Effect of laryngeal hemiplegia and laryngoplasty
2034 on airway flow mechanics in exercising horses. *Am J Vet Res* 1986;47:16–20.
- 2035 20. Fulton IC, Stick JA, Derksen FJ. Laryngeal reinnervation in the horse. *Vet Clin North*
2036 *Am Equine Pract* 2003;19:189–208.
- 2037 21. Rakesh V, Ducharme NG, Cheetham J, et al. Implications of different degrees of
2038 arytenoid cartilage abduction on equine upper airway characteristics. *Equine Vet J*
2039 2008;40:629–635.
- 2040 22. Tate LP., Corbett WT, Bishop BJ, et al. Blood Gas Tensions, Acid-base Status, Heart
2041 Rates, and Venous Profiles in Exercising Horses with Laryngeal Hemiplegia Before and
2042 After Corrective Surgery. *Vet Surg* 1993;22:177–183.
- 2043 23. Fleming G. Laryngismus paralytica (“roaring”). *Vet J Ann Comp Pathol*; 1882;14:1-
2044 12.
- 2045 24. Poncet PA, Montavon S, Gaillard C, et al. A Preliminary Report on the Possible
2046 Genetic-Basis of Laryngeal Hemiplegia. *Equine Vet J* 1989;21:137–138.
- 2047 25. Cook WR. Diagnosis and Grading of Hereditary Recurrent Laryngeal Neuropathy in
2048 the Horse. *J Equine Vet Sci* 1988;8:432–455.
- 2049 26. Dixon PM, McGorum BC, Railton DI, et al. Laryngeal paralysis: a study of 375 cases
2050 in a mixed-breed population of horses. *Equine Vet J* 2001;33:452–458.
- 2051 27. Hahn CN, Matiasek K, Dixon PM, et al. Histological and ultrastructural evidence that
2052 recurrent laryngeal neuropathy is a bilateral mononeuropathy limited to recurrent laryngeal
2053 nerves. *Equine Vet J* 2008;40:666–672.
- 2054 28. Goulden BE, Anderson LJ. Equine Laryngeal Hemiplegia, Physical Characteristics of
2055 Affected Animals. *N Z Vet J* 1981;29:151–154.
- 2056 29. Beard WL, Hayes HM. Risk-Factors for Laryngeal Hemiplegia in the Horse. *Prev Vet*
2057 *Med* 1993;17:57–63.
- 2058 30. Lane JG, Ellis DR, Greet T. Observations on the Examination of Thoroughbred
2059 Yearlings for Idiopathic Laryngeal Hemiplegia. *Equine Vet J* 1987;19:531–536.
- 2060 31. Brakenhoff JE, Holcombe SJ, Hauptman JG, et al. The prevalence of laryngeal disease
2061 in a large population of competition draft horses. *Vet Surg* 2006;35:579–583.
- 2062 32. Janicek JC, Ketzner KM. Performance-limiting laryngeal disorders. *VetFolio, Int Med*
2063 2008;3;8.

- 2064 33. Dahlberg JA, Valdes-Martinez A, Boston RC, et al. Analysis of conformational
2065 variations of the cricoid cartilages in Thoroughbred horses using computed tomography.
2066 Equine Vet J 2011;43:229–234.
- 2067 34. Cheetham J, Radcliffe CR, Ducharme NG, et al. Neuroanatomy of the equine dorsal
2068 cricoarytenoid muscle: Surgical implications. Equine Vet J 2008;40:70–75.
- 2069 35. Rhee HS, Steel CM, Derksen FJ, et al. Immunohistochemical analysis of laryngeal
2070 muscles in normal horses and horses with subclinical recurrent laryngeal neuropathy. J
2071 Histochem Cytochem 2009;57:787–800.
- 2072 36. Poole DC, Erickson HH. Highly athletic terrestrial mammals: horses and dogs. Compr
2073 Physiol 2011;1:1–37.
- 2074 37. Bassett DR, Howley ET. Limiting factors for maximum oxygen uptake and
2075 determinants of endurance performance. Med Sci Sports Exerc 2000;32:70–84.
- 2076 38. Franklin SH, Van Erck-Westergren E, Bayly WM. Respiratory responses to exercise in
2077 the horse. Equine Vet J 2012;44:726–732.
- 2078 39. Christley RM, Evans DL, Hodgson DR, et al. Blood gas changes during incremental
2079 and sprint exercise. Equine Vet J Suppl 1999:24–26.
- 2080 40. Shappell KK, Derksen FJ, Stick JA, et al. Effects of ventriculectomy, prosthetic
2081 laryngoplasty, and exercise on upper airway function in horses with induced left laryngeal
2082 hemiplegia. Am J Vet Res 1988;49:1760–1765.
- 2083 41. Dupuis M-C, Zhang Z, Druet T, et al. Results of a haplotype-based GWAS for
2084 recurrent laryngeal neuropathy in the horse. Mamm Genome 2011;22:613–620.
- 2085 42. Goulden BE, Anderson LJ. Equine Laryngeal Hemiplegia, some Clinical Observations.
2086 N Z Vet J 1981;29:194–198.
- 2087 43. Dixon PM, Hahn CN, Barakzai SZ. Recurrent laryngeal neuropathy (RLN) research:
2088 Where are we and to where are we heading? Equine Vet J 2009;41:324–327.
- 2089 44. Fulton IC, Anderson BH, Stick JA, et al. Larynx. In: Auer JA, Stick JA. Equine
2090 surgery 3rd ed. W B Saunders Company; 2006:566–590.
- 2091 45. Garrett KS, Embertson RM, Woodie JB, et al. Ultrasound features of arytenoid
2092 chondritis in Thoroughbred horses. Equine Vet J 2013;45:598–603.
- 2093 46. Allen KJ, Franklin SH. Comparisons of overground endoscopy and treadmill
2094 endoscopy in UK Thoroughbred racehorses. Equine Vet J 2010;42:186–191.
- 2095 47. Franklin SH. Dynamic collapse of the upper respiratory tract: A review. Equine Vet Ed
2096 2008;20:212–224.
- 2097 48. Garrett KS, Woodie JB, Embertson RM, et al. Diagnosis of laryngeal dysplasia in five
2098 horses using magnetic resonance imaging and ultrasonography. Equine Vet J 2009;41:766–
2099 771.

- 2100 49. Davidson EJ, Martin BB, Parente EJ. Use of successive dynamic videoendoscopic
2101 evaluations to identify progression of recurrent laryngeal neuropathy in three horses. *J Am*
2102 *Vet Med Assoc* 2007;230:555–558.
- 2103 50. Brown JA, Derksen FJ, Stick JA, et al. Effect of laryngoplasty on respiratory noise
2104 reduction in horses with laryngeal hemiplegia. *Equine Vet J* 2004;36:420–425.
- 2105 51. Leutton JL, Lumsden JM. Dynamic respiratory endoscopic findings pre- and post
2106 laryngoplasty in Thoroughbred racehorses. *Equine Vet J* 2015:531-536.
- 2107 52. Lane JG, Bladon B, Little DR, et al. Dynamic obstructions of the equine upper
2108 respiratory tract. Part 2: Comparison of endoscopic findings at rest and during high-speed
2109 treadmill exercise of 600 Thoroughbred racehorses. *Equine Vet J* 2006;38:401–407.
- 2110 53. Lane JG, Bladon B, Little DR, et al. Dynamic obstructions of the equine upper
2111 respiratory tract. Part 1: Observations during high-speed treadmill endoscopy of 600
2112 Thoroughbred racehorses. *Equine Vet J* 2006;38:393–399.
- 2113 54. Lane JG. 5-point grading system of laryngeal function in horses during quiet breathing.
2114 In *Proceedings of a workshop on equine recurrent laryngeal neuropathy*. Havemeyer
2115 Foundation Monograph Series No. 11. 2003;24-26
- 2116 55. Ducharme NG 4-point grading system for equine laryngeal function. In *Proceedings of*
2117 *a workshop on equine recurrent laryngeal neuropathy*. Havemeyer Foundation Monograph
2118 Series No. 11. 2003;21-24
- 2119 56. Ducharme NG, Hackett RP, Fubini SL, et al. The reliability of endoscopic examination
2120 in assessment of arytenoid cartilage movement in horses. Part II. Influence of side of
2121 examination, reexamination, and sedation. *Vet Surg* 1991;20:180–184.
- 2122 57. Barakzai SZ, Dixon PM. Correlation of resting and exercising endoscopic findings for
2123 horses with dynamic laryngeal collapse and palatal dysfunction. *Equine Vet J* 2011;43:18–
2124 23.
- 2125 58. Kelly PG, Reardon RJM, Johnston MS, et al. Comparison of dynamic and resting
2126 endoscopy of the upper portion of the respiratory tract in 57 Thoroughbred yearlings.
2127 *Equine Vet J* 2013;45:700–704.
- 2128 59. Garrett KS, Woodie JB, Embertson RM. Association of treadmill upper airway
2129 endoscopic evaluation with results of ultrasonography and resting upper airway endoscopic
2130 evaluation. *Equine Vet J* 2010;43:365–371.
- 2131 60. Rakestraw PC, Hackett RP, Ducharme NG, et al. Arytenoid Cartilage Movement in
2132 Resting and Exercising Horses. *Vet Surg* 1991;20:122–127.
- 2133 61. Strand E, Martin GS, Haynes PF, et al. Career racing performance in Thoroughbreds
2134 treated with prosthetic laryngoplasty for laryngeal neuropathy: 52 cases (1981–1989). *J*
2135 *Am Vet Med Assoc* 2000;217:1689–1696.
- 2136 62. Taylor SE, Barakzai SZ, Dixon P. Ventriculocordectomy as the sole treatment for
2137 recurrent laryngeal neuropathy: long-term results from ninety-two horses. *Vet Surg*
2138 2006;35:653–657.

- 2139 63. Brown JA, Derksen FJ, Stick JA, et al. Ventriculocordectomy reduces respiratory noise
2140 in horses with laryngeal hemiplegia. *Equine Vet J* 2003;35:570–574.
- 2141 64. Cadiot PJ. *Roaring in Horses: Its Pathology and Treatment*. 1892.
- 2142 65. Marks D, Mackay-Smith MP, Cushing LS, et al. Use of a Prosthetic Device for
2143 Surgical Correction of Laryngeal Hemiplegia in Horses. *J Am Vet Med Assoc*
2144 1970;157:157-163.
- 2145 66. Goulden BE, Anderson LG. Equine laryngeal hemiplegia. Part III. Treatment by
2146 laryngoplasty. *NZ Vet J* 1982;30:1–5.
- 2147 67. Kidd JA, Slone DE. Treatment of laryngeal hemiplegia in horses by prosthetic
2148 laryngoplasty, ventriculectomy and vocal cordectomy. *Vet Rec* 2002;150:481–484.
- 2149 68. Dixon RM, McGorum BC, Railton DI, et al. Long-term survey of laryngoplasty and
2150 ventriculocordectomy in an older, mixed-breed population of 200 horses. Part 1:
2151 Maintenance of surgical arytenoid abduction and complications of surgery. *Equine Vet J*
2152 2003;35:389–396.
- 2153 69. Davenport-Goodall CL, Parente EJ. Disorders of the larynx. *Vet Clin North Am*
2154 *Equine Pract* 2003;19:169–187.
- 2155 70. Speirs VC, Bourke JM, Anderson GA. Assessment of the efficacy of an abductor
2156 muscle prosthesis for treatment of laryngeal hemiplegia in horses. *Aust Vet J*
2157 1983;60:294–299.
- 2158 71. Robertz A, Ohnesorge B, Boening KJ. Laryngoplasty with metallic implants -
2159 biomechanical tension test of the arytenoid and cricoid of the horse using metallic
2160 prostheses. *Pferdeheilkunde* 2009;25:205–210.
- 2161 72. Rossignol F, Vitte A, Boening J, et al. Laryngoplasty in standing horses. *Vet Surg*
2162 2015;44:341–347.
- 2163 73. Robertson JT. Laryngoplasty: a novel prosthesis. *Equine Vet J* 2000;32:5–6.
- 2164 74. Parente EJ, Birks EK, Habecker P. A modified laryngoplasty approach promoting
2165 ankylosis of the cricoarytenoid joint. *Vet Surg* 2011;40:204–210.
- 2166 75. Ahern BJ, Boston RC, Parente EJ. In vitro mechanical testing of an alternate
2167 laryngoplasty system (ALPS) for horses. *Vet Surg* 2012;41:918–923.
- 2168 76. McGorum BC. Laryngeal paralysis with known and suspected causes. In: *Equine*
2169 *respiratory medicine and surgery*. Philadelphia: Elsevier 2007:479-481.
- 2170 77. Davenport CLM, Tulleners EP, Parente EJ. The effect of recurrent laryngeal
2171 neurectomy in conjunction with laryngoplasty and unilateral ventriculocordectomy in
2172 thoroughbred racehorses. *Vet Surg* 2001;30:417–421.
- 2173 78. Greet TR, Baker GJ, Lee R. The Effect of Laryngoplasty on Pharyngeal Function in the
2174 Horse. *Equine Vet J* 1979;11:153–158.

- 2175 79. Dean PW, Nelson JK, Schumacher J. Effects of age and prosthesis material on in vitro
2176 cartilage retention of laryngoplasty prostheses in horses. *Am J Vet Res* 1990;51:114–117.
- 2177 80. Schumacher J, Wilson AM, Pardoe C, et al. In vitro evaluation of a novel prosthesis for
2178 laryngoplasty of horses with recurrent laryngeal neuropathy. *Equine Vet J* 2000;32:43–46.
- 2179 81. Mason BJ, Riggs CM, Cogger N. Cohort study examining long-term respiratory health,
2180 career duration and racing performance in racehorses that undergo left-sided prosthetic
2181 laryngoplasty and ventriculocordectomy surgery for treatment of left-sided laryngeal
2182 hemiplegia. *Equine Vet J* 2013;45:229–234.
- 2183 82. Barnett TP, O'Leary JM, Dixon PM, et al. Characterisation of palatal dysfunction after
2184 laryngoplasty. *Equine Vet J* 2014;46:60–63.
- 2185 83. Mathews KG, Roe S, Stebbins M, et al. Biomechanical Evaluation of Suture Pullout
2186 from Canine Arytenoid Cartilages: Effects of Hole Diameter, Suture Configuration, Suture
2187 Size, and Distraction Rate. *Vet Surg* 2004;33:191–199.
- 2188 84. Rossignol F, Perrin R, Desbrosse F, et al. In vitro comparison of two techniques for
2189 suture prosthesis placement in the muscular process of the equine arytenoid cartilage. *Vet*
2190 *Surg* 2006;35:49–54.
- 2191 85. Kelly JR, Carmalt J, Hendrick S, et al. Biomechanical comparison of six suture
2192 configurations using a large diameter polyester prosthesis in the muscular process of the
2193 equine arytenoid cartilage. *Vet Surg* 2008;37:580–587.
- 2194 86. Cheetham J, Witte TH, Soderholm LV, et al. In vitro model for testing novel implants
2195 for equine laryngoplasty. *Vet Surg* 2008;37:588–593.
- 2196 87. Witte TH, Cheetham J, Rawlinson JJ, et al. A transducer for measuring force on
2197 surgical sutures. *Can J Vet Res* 2010;74:299–304.
- 2198 88. Witte TH, Cheetham J, Soderholm LV, et al. Equine laryngoplasty sutures undergo
2199 increased loading during coughing and swallowing. *Vet Surg* 2010;39:949–956.
- 2200 89. Cramp P, Derksen FJ, Stick JA, et al. Effect of magnitude and direction of force on
2201 laryngeal abduction: Implications for the nerve-muscle pedicle graft technique. *Equine Vet*
2202 *J* 2010;41:328–333.
- 2203 90. Herde I, Boening KJ, Sasse H. Arytenoid cartilage retention of laryngoplasty in horses-
2204 in vitro assessment of effect of age, placement site, and implantation technique. *Proc Am*
2205 *Assoc Equine Pract*; 2001;47:115-119.
- 2206 91. Ahern BJ, Van Eps AW, Boston RC, et al. In vitro comparison of 3 techniques of
2207 prosthesis attachment to the muscular process of the equine arytenoid cartilage. *Vet Surg*
2208 2017;35:579.
- 2209 92. Ahern BJ, Parente EJ. Mechanical evaluation of the equine laryngoplasty. *Vet Surg*
2210 2010;39:661–666.
- 2211 93. Cheetham J, Witte TH, Rawlinson JJ, et al. Intra-articular stabilisation of the equine
2212 cricoarytenoid joint. *Equine Vet J* 2008;40:584–588.

- 2213 94. Hawkins JF, Couetil L, Miller MA. Maintenance of arytenoid abduction following
2214 carbon dioxide laser debridement of the articular cartilage and joint capsule of the
2215 cricoarytenoid joint combined with prosthetic laryngoplasty in horses: an in vivo and in
2216 vitro study. *Vet J* 2014;199:275–280.
- 2217 95. Bohanon TC, Beard WL, Robertson JT. Laryngeal hemiplegia in draft horses. A
2218 review of 27 cases. *Vet Surg* 1990;19:456–459.
- 2219 96. Scherzer S, Hainisch EK. Evaluation of a canine cranial cruciate ligament repair
2220 system for use in equine laryngoplasty. *Vet Surg* 2005;34:548–553.
- 2221 97. Ahern BJ. Biomechanics of Prosthetic Laryngoplasty. In; *Advances in equine upper
2222 respiratory surgery*. Hawkins J. Hoboken: John Wiley & Sons, Inc.; 2014:35–41.
- 2223 98. Dart A, Tee E, Brennan M, et al. Effect of prosthesis number and position on rima
2224 glottidis area in equine laryngeal specimens. *Vet Surg* 2009;38:452–456.
- 2225 99. Froydenlund TJ, Dixon PM. A review of equine laryngoplasty complications. *Equine
2226 Vet Educ* 2014;26:98–106.
- 2227 100. Hardcastle MR, Pauwels FET, Collett MG. Clinicopathologic Observations on
2228 Laryngoplasty Failure in a Horse. *Vet Surg* 2012;41:649–653.
- 2229 101. Dixon PM, Parkin TD, Collins N, et al. Equine paranasal sinus disease: A long-term
2230 study of 200 cases (1997-2009): Treatments and long-term results of treatments. *Equine
2231 Vet J* 2011;44:272–276.
- 2232 102. Ahern BJ, Parente EJ. Surgical Complications of the Equine Upper Respiratory Tract.
2233 *Veterinary Clinics of North America: Equine Practice* 2008;24:465–484.
- 2234 103. McClellan NR, Santschi EM, Hurcombe SDA, et al. An ex vivo model to evaluate the
2235 effect of cyclical adductory forces on maintenance of arytenoid abduction after prosthetic
2236 laryngoplasty performed with and without mechanical arytenoid abduction. *Vet Surg*
2237 2014;43:598–605.
- 2238 104. Willsallen H, Heller J, Kark L, et al. In vitro mechanical testing of braided
2239 polyurethane elastic fiber and braided polyester for equine laryngoplasty. *Vet Surg*
2240 2015;44:223–230.
- 2241 105. Markwell HJ, Mueller POE. Ex Vivo Mechanical Evaluation of a Sternal ZipFix
2242 ®Implant for Prosthetic Laryngoplasty in Horses. *Vet Surg* 2016;45:450–455.
- 2243 106. Parente EJ, Hawkins JF. Prosthetic laryngoplasty. In: *Advances in Equine Upper
2244 Respiratory Surgery*. Hawkins J. Hoboken: John Wiley & Sons, Inc.; 2014:30-35.
- 2245 107. Bischofberger AS, Hadidane I, Wereszka MM, et al. Effect of Age and Prostheses
2246 Location on Rima Glottidis Area in Equine Cadaveric Larynges. *Vet Surg* 2013;42:286–
2247 290.
- 2248 108. Tatarniuk DM, Carmalt JL, Allen AL. Induration of the cricoid cartilage complicates
2249 prosthetic laryngoplasty in a horse. *Vet Surg* 2010;39:128–130.

- 2250 109. Bischofberger AS, Wereszka MM, Hadidane I, et al. Optimal tension, position, and
2251 number of prostheses required for maximum rima glottidis area after laryngoplasty. *Vet*
2252 *Surg* 2013;42:280–285.
- 2253 110. Perkins JD, Meighan H, Windley Z, et al. In vitro effect of ventriculocordectomy
2254 before laryngoplasty on abduction of the equine arytenoid cartilage. *Vet Surg*
2255 2011;40:305–310.
- 2256 111. Barakzai SZ, Boden LA, Dixon PM. Postoperative Race Performance is Not
2257 Correlated with Degree of Surgical Abduction After Laryngoplasty in National Hunt
2258 Thoroughbred Racehorses. *Vet Surg* 2009;38:934–940.
- 2259 112. Biasutti S, Dart AJ, Jeffcott LB. A review of recent developments in the clinical
2260 application of prosthetic laryngoplasty for recurrent laryngeal neuropathy: Indications,
2261 complications and outcome. *Equine Veterinary Education* 2017;29:337–345.
- 2262 113. Lechartier A, Rossignol F, Brandenberger O, et al. Mechanical Comparison of 3
2263 Anchoring Techniques in the Muscular Process for Laryngoplasty in the Equine Larynx.
2264 *Vet Surg* 2015;44:333–340.
- 2265 114. Witte TH, Mohammed HO, Radcliffe CH, et al. Racing performance after combined
2266 prosthetic laryngoplasty and ipsilateral ventriculocordectomy or partial arytenoidectomy:
2267 135 Thoroughbred racehorses competing at less than 2400 m (1997-2007). *Equine Vet J*
2268 2009;41:70–75.
- 2269 115. Ahern BJ, van Eps AW, Franklin SH. Mechanical testing of a prototype dynamic
2270 laryngoplasty system (DLPS) - submitted. *Veterinary Surgery*.
- 2271 116. Jansson N, Ducharme NG, Hackett RP, et al. An in vitro comparison of cordopexy,
2272 cordopexy and laryngoplasty, and laryngoplasty for treatment of equine laryngeal
2273 hemiplegia. *Vet Surg* 2000;29:326–334.
- 2274 117. Bienert-Zeit A, Roetting A, Reichert C, et al. Laryngeal fistula formation after
2275 laryngoplasty in two Warmblood mares. *Equine Vet Educ* 2014;26:88–92.
- 2276 118. Holcombe SJ, Beard WL, Hinchcliff KW, et al. Effect of sternothyrohyoid myectomy
2277 on upper airway mechanics in normal horses. *J Appl Physiol* 1985;77:2812–2816.
- 2278 119. Ahern BJ, Lim Y, van Eps AW, et al. In vitro evaluation of the efficacy of a prototype
2279 dynamic laryngoplasty system (DLPS) to affect arytenoid abduction - submitted.
2280 *Veterinary Surgery*.
- 2281 120. Curtis RA, Kusano K, Evans DL, et al. Reliability of cardiorespiratory measurements
2282 with a new ergospirometer during intense treadmill exercise in Thoroughbred horses. *Vet J*
2283 2005;169:223–231.
- 2284 121. Tetens J, Derksen FJ, Stick JA, et al. Efficacy of prosthetic laryngoplasty with and
2285 without bilateral ventriculocordectomy as treatments for laryngeal hemiplegia in horses.
2286 *Am J Vet Res* 1996;57:1668–1673.
- 2287 122. Raja Abdullah RI, Yu Long A, Mohd Amran MA, et al. Optimisation of Machining
2288 Parameters for Milling Polyetheretherketones (PEEK) Biomaterial. *App Mech Mat*

2289 2015;699:198–203.

2290 123. Malmstrom H, Carstensen J, Simonsen E. Experience with Implanted Subcutaneous
2291 Ports for Intraperitoneal Chemotherapy in Ovarian Cancer. *Gynecol Oncol* 1994;54:27–34.

2292 124. Ahern BJ, Lukas E, Wilkie E, et al. Evaluation of a prototype dynamic laryngoplasty
2293 system (DLPS) in vitro using a static airflow system - submitted. *Veterinary Surgery*.

2294